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ABSTRACT 
 
 
Ovarian cancer is the leading cause of gynecological cancer death in the United 
States.  Even though no single genetic alteration can be attributed to all ovarian cancers, 
90% of ovarian tumors express telomerase, a ribonucleoprotein that elongates telomeric 
(TTAGGG)n repeats de novo.  In normal somatic cells, telomerase is absent.  In cancer 
cells, the re-expression of telomerase allows senescence to be bypassed contributing to 
cellular immortalization, a key step for cellular transformation, making telomerase a 
potentially important target for therapeutic intervention. 
Ovarian cancer cells secrete vascular endothelial growth factor (VEGF) and 
lysophosphatidic acid (LPA) that feedback through their receptors present on ovarian 
cancer cells to promote cell growth.  Since telomerase can be regulated by growth factors, 
I examined VEGF regulation of telomerase activity and the possible contribution of LPA 
as an upstream regulator of VEGF-mediated telomerase activity in ovarian cancer.  My 
data reveal that both VEGF and LPA upregulate telomerase activity by ERK 1/2-
dependent transcriptional activation within the -976 to the -378 bp hTERT promoter 
regions where Sp1 is one of the major mediators of VEGF- and LPA-induced 
transactivation of hTERT.  It also identifies telomerase as a novel molecular target of 
 xii 
LPA as well as a target of VEGF in non-endothelial cells.  In addition I found that, 
vitamin E, a dietary supplement able to degrade and suppress LPA activity, consistently 
abrogrates LPA-mediated telomerase activity through transcriptional inhibition of the 
hTERT -976 to -578 bp promoter regions.   
Lastly, since epidermal growth factor (EGF) promotes ovarian surface epithelial 
(OSE) cell growth and EGF receptors are frequently constitutively activated in ovarian 
cancers, the potential contribution of EGF in the regulation of telomerase activity was 
also examined.  While none of the ovarian cancer cell lines examined produced large 
amounts of EGF, EGF stimulation of telomerase activity was mediated by Sp1 and c-Myc 
transcription factors within the hTERT core promoter in an ERK 1/2 /Pyk2-dependent 
manner. 
In conclusion, my research shows differential regulation of telomerase activity by 
growth factor and/or anti-oxidant nutraceuticals.  In the future, these factors may be 
exploited as adjuvant therapy for improved chemotherapeutic benefit to decrease the 
mortality associated with ovarian cancer.   
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Chapter I 
Introduction 
Ovarian Cancer 
Ovarian cancer, the silent killer, presents a serious clinical challenge because 
symptoms do not develop or are not recognized until the disease is in its advanced stages, 
contributing to poor prognosis.  It is the fourth leading cause of cancer death among 
women after lung, breast, and colorectal cancer [1] and is associated with a 1.7% lifetime 
risk [2].  It is estimated that 22,220 new cases are diagnosed in the United States (US) 
annually and that 16,210 women die annually from this disease [1].  Five-year survival 
rates for ovarian cancer vary based on stage and grade of the tumor [1].  In the United 
States, the overall survival rate for stage I is 93%, stage II is 70%, stage III is 37%, and 
stage IV is 25% [1].  However, only about 20% of patients are diagnosed at stage I, 
whereas approximately two-thirds of patients are diagnosed at stage III or IV [1].  
Currently for ovarian cancer, there is no known preinvasive disease condition and, 
unfortunately, ovarian cancer is relatively asymptomatic until later stages.  Even when 
symptoms do present, they are often mistaken as gastrointestinal problems or menopausal 
symptoms.  Therefore, there is often a delay in diagnosis, accounting for predominance of 
cases that are identified in late stages of the disease.   
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Origin of Ovarian Cancer from Ovarian Surface Epithelium 
Over 85% of ovarian tumors arise from the ovarian surface epithelium (OSE) [3-
5].  Epithelial ovarian cancers are thought to arise from the single layer of cells that 
covers the ovary or that lines cysts immediately beneath the ovarian surface [3-5].  These 
cells are generally quiescent, but proliferate following ovulation to repair the defect 
created by rupture of a follicle [6-8].   In addition, cyst formation is more frequently 
observed in the later reproductive years, which coincides with the average age of ovarian 
carcinoma [3].  When these cysts form, they are usually sealed off from the surface 
similar to a crypt-like environment exposing them to doses of hormones and growth 
factors different from those cells still on the ovarian surface [9]. 
In support of these observations, examination of the OSE of ovaries removed 
prophylatically from women with a familial history of breast and ovarian tumors have 
revealed numerous histologic changes.  Such changes include epithelial papillomatosis, 
numerous inclusion cysts, deep invaginations, epithelial pseudostratification, and 
hyperactive stroma [8].  Since the OSE originates in the coelomic epithelium overlying 
the gonadal ridge [9], the OSE is embryologically related to other gynecological tissues 
[10], including the epithelial lining the oviduct, uterus and vagina.  Consequently, ovarian 
tumors often mimic these tissues derived from the coelomic epithelium and are classified 
as serous, endometriod and mucinous ovarian cancers [11].   
In vitro models also support the origin of ovarian cancer from the OSE.  For 
instance,  Godwin et al demonstrated that repeated passaging, which mimicked post-
ovulatory repair-driven OSE proliferation, could transform rat OSE cells in culture [12], 
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while separate studies by Nicosia et al and Auersperg et al also demonstrated how the 
highly proliferative capacity of rabbit and human OSE cells can lead to formation of 
preneoplastic lesions [13-15].  In addition, epithelial irritation by external contaminants, 
such as fibers, can promote tumorigenesis [16].  Since the OSE maintains a direct 
connection with the external environment, the hypothesis of external irritants causing 
ovarian cancer initially gained support because women commonly used asbestos-
contaminated talcs for genital hygiene [16].   
Epidemiological Studies of Ovarian Cancer 
Epidemiological studies also support the hypothesis that ovarian neoplasms arise 
primarily from the OSE.  A well accepted theory is the incessant ovulation hypothesis 
described by M.F. Fathalla in 1971 [17].  This study observed that nulliparous women 
had a higher incidence of ovarian cancer than multiparous women by 30 to 60% [18].  In 
addition, studies by Lowry et al and Francheschi et al showed that oral contraceptive use 
or breast feeding are protective against ovarian cancer as they suppress ovulation [19, 
20].  In summary, this hypothesis proposes that repeated traumatic rupture and 
expeditious repair of the OSE during each ovulatory cycle could result in the 
accumulation of genetic mutations that allow for transformation of these cells [17].   
Genetic Predisposition for Ovarian Cancer 
Most epithelial ovarian tumors are sporadic, with familial or hereditary patterns 
accounting for 5 to 10% of all malignancies [21].  Two genes often associated with 
genetic predisposition to ovarian cancer are BRCA1 and BRCA2 located on 
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chromosomes 17 and 13, respectively [22].  These mutations are passed via autosomal 
dominant inheritance.  Women who have a mutation in the BRCA1 gene are associated 
with a lifetime risk of ovarian cancer as high as 28 to 44% while the risk for women with 
a BRCA2 mutation is as high as 27% compared to the general population [23].   
Ovarian carcinoma may also arise in families with hereditary non-polyposis 
colorectal cancer (HNPCC) or Lynch II syndrome [24, 25].  The two most frequently 
mutated genes in HNPCC are hMSH2 and hMLH1, and the risk of ovarian carcinoma is 
raised in carriers of mutations in either of these genes [24, 26].    The cumulative risk of 
ovarian cancer in HNPCC families is more than 12% and they are frequently diagnosed at 
a younger age than the general population [26, 27].  In addition, most tumors are low 
stage, well differentiated or moderately differentiated carcinomas [26, 27]. 
Diagnostic and Prognostic Screening Modalities 
Currently, there is no standardized strategy for early detection of ovarian cancer.  
However, potential screening modalities including the use of cancer antigen 125 (CA125) 
and lysophosphatidic acid (LPA) as diagnostic tools, and vascular endothelial growth 
factor (VEGF) as a prognostic tool has been explored.   
CA125 is a glycoprotein that is expressed by tissues derived from coelomic 
epithelium, which includes cells of the pleura, pericardium, peritoneum, and mullerian 
tissue [28].  It is not found in normal ovarian epithelium, but it is overexpressed by serous 
and mucinous papillary tumors [29].  However, since CA125 is expressed by tissues 
derived from coelomic epithelium, the value can be elevated with any condition that 
causes peritoneal or mesothelial inflammation.  Furthermore, in ovarian cancer patients, 
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CA125 levels are not elevated above normal ranges in over half of the patients with 
early-stage disease [30, 31].  Due to the nonspecific nature of CA125 expression, it has 
not been shown to be effective as a sole screening modality in the detection of early 
ovarian cancer. 
In contrast, LPA, a natural occurring phospholipid, is found elevated in plasma 
and ascites of ovarian cancer patients.  Two studies by Xu et al and Sutphen et al showed 
that patients with ovarian cancer had significantly higher plasma LPA levels as compared 
with the control group.  Nine of ten patients with stage I disease had elevated levels as 
well as in all 24 patients with stage II-IV disease [32].  In contrast, corresponding CA125 
values only showed elevation above 35 U/mL in two of the nine patients with stage I 
disease, and only 13 of the 24 patients with stage II-IV disease had elevated CA125 
levels [32].  In regards to healthy controls, five of the 48 patients had elevated serum 
levels of LPA and 4 of the 17 patients with benign gynecologic conditions had elevated 
serum levels of LPA [32].  The Sutphen et al study in 2004 corroborated LPA levels to be 
elevated preoperatively in ovarian cancer patients as compared with control samples [33].  
In addition, they studied 22 cases with both preoperative and postoperative samples to 
determine whether LPA could also be used as a prognostic tool [33].  They found that 
postoperative levels of total LPA were significantly lower than preoperative levels (p ≤ 
0.05) [33].  Furthermore, Sutphen et al proposed to detect LPA by surface-enhanced 
Raman scattering (SERS) using silver nanoparticles to eliminate the need for partial 
purification of samples by thin layer chromatography (TLC) prior to analysis using 
chromatography and mass spectrometry assays in cancer screening, which will allow for 
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a more specific and sensitive detection of LPA [34].  In conclusion, these studies show 
LPA as a potential biomarker for ovarian cancer. 
VEGF, an important proangiogenic regulator [35, 36], has been shown to be 
elevated in ovarian cancer cyst fluid as compared with benign, borderline, or functional 
cysts [37].  Several studies have shown that patients whose disease recurred, progressed, 
or who died from the disease displayed significantly higher tumor staining of VEGF 
suggesting a correlation between induced neoangiogenesis and tumor progression and/or 
metastases [38-42].   Therefore, high VEGF levels in ovarian cancer cyst fluid may 
represent an indicator of malignancy and tumor progression in the ovary.   
Treatments 
Despite initial tumor response rates of 80% to first-line taxane- and platinum-
based chemotherapy and surgical debulking [43, 44], most women with advanced ovarian 
carcinoma will ultimately develop drug-resistant disease [45, 46].  The use of second-line 
chemotherapeutic agents, such as doxorubicin, topotecan, gemcitabine, tamoxifen, and 
vinorelbine, can lead to a response rate of approximately 15% to 25% [47].  Therefore, it 
is imperative that novel and/or improved therapeutic modalities for ovarian cancer are 
developed.   
In response, molecular targeting strategies for cancer therapy are being explored 
because of their potential to specifically target the tumor when combined with current 
conventional chemotherapy modalities.  Since 35 to 70% of ovarian carcinomas 
overexpress EGF receptor (EGFR) [48], and VEGF is elevated in ascites of ovarian 
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cancer patients [37], these are two promising molecules in the treatment of ovarian 
cancer. 
EGFR is dysregulated in many malignancies and its signaling pathway plays a 
pivotal role in controlling tumor growth and progression, apoptosis, and angiogenesis 
[49, 50].  In addition, dysregulation of EGFR has been associated with chemoresistance 
and poor prognosis [51].  Monoclonal antibodies and small-molecule EGFR tyrosine 
kinase inhibitors (TKIs) are the most promising and well studied EGFR inhibitor 
strategies in the treatment of malignancies refractory to conventional chemotherapy.  
They both target the same receptor, but their mechanisms of receptor inhibition are 
different.  Monoclonal antibodies block the extracellular ligand-binding portion of the 
EGFR and interfere with its activation.  In contrast, TKIs block induction of the 
intracellular tyrosine kinase-mediated signaling pathways.   
Phase II clinical trials of Tarceva® (OSI-774, erlotinib), a small-molecule EGFR 
tyrosine kinase inhibitor, demonstrated an acceptable safety profile during moderately 
long-term administration in 34 women with EGFR-overexpressing ovarian tumors treated 
with OSI-774 by daily oral dosing [52].  Randomized trials are needed to further evaluate 
OSI-774s potential in the treatment of ovarian cancer in conjunction with conventional 
chemotherapy.   
Similar techniques are being implemented to target the tumors vasculature, 
which nourishes the tumor by supplying oxygen and nutrients, allowing it to grow and 
metastasis [35, 36].  Vascular disrupting agents (VDAs) work by causing the endothelials 
cells, cells that line the inside of blood vessels, to change shape and collapse in order to 
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shut off blood flow to tumors, leading to cell death [53, 54].  To date, two types of 
VDAs, small molecule and ligand directed are being pursuit.  Small molecule VDAs 
damage the structure of endothelial cells by interfering with the cells cellular 
scaffolding, or tubulin, important in helping cells maintain their shape, or by releasing 
tumor necrosis factor, which leads to the collapse of blood vessels [53, 55, 56].  Ligand-
directed VDAs use antibodies, peptides, or growth factors to target toxins or 
procoagulants to the tumor endothelium.   
One small molecule VDA in clinical trials with advanced ovarian cancer patients 
is combretastatin A-4 phosphate (CA4P), which triggers a change in the shape of the 
endothelial cells lining tumor blood vessels, blocking the flow of blood to a tumor and 
depriving it of oxygen and nutrients essential to its survival.  In a Phase Ib study that 
combined CA4P with the chemotherapy drugs paclitaxel or carboplatin, six of nine 
patients with advanced ovarian cancer showed 50% tumor shrinkage [57].  In summary, 
small molecule VDAs are attractive because of their specificity in targeting the tumor 
vascular system.  Future progress including advanced clinical trials will enable these 
agents to reach cancer patients either as single agents or in combination therapy.   
The antiangiogenic agents are the second group of vascular targeted therapies.  
The antiangiogenic group differs from the VDAs in that the antiangiogenic group 
interferes with new vessel formation and therefore has a preventive action, requires 
chronic administration, and is likely to be of particular benefit in early stage or 
asymptomatic metastatic disease [58].   
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One prospective antiangiogenic agent against ovarian cancer is bevacizumab, a 
humanized recombinant antibody that prevents vascular endothelial growth factor 
binding and inhibits angiogenesis and tumor growth.  Randomized trials have shown 
statistically significant improvements in progression-free and overall survival when 
bevacizumab is combined with chemotherapy in several solid tumors.  In the 
Gynecologic Oncology Group 170-D study, 63 patients with recurrent ovarian cancer 
were treated with 15 mg/kg of bevacizumab intravenously every three weeks [59].  The 
overall response rate was 17.7% and 38.7% of patients were progression free at 6 or more 
months [59].  Since antiangiogenic therapies require high dosages, current data suggest 
that antiangiogenic agents such as bevacizumab may be best used upfront or in 
combination with chemotherapy in patients going through their initial chemotherapy.   
Future directions lie in understanding the molecular mechanism(s) of action of 
these promising drugs currently undergoing clinical evaluation.  Increased understanding 
of their molecular targets and cell signaling processes involved might aid in improving 
the current drugs and/or assist in the development of second generation of these agents.   
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Telomeres and Telomerase 
Telomeres 
Early studies by Muller and McClintock showed the ends of chromosomes are 
capped by telomeres to prevent chromosome fusions [60, 61].  In humans, telomeres are 
usually 10 kb long and consist of guanine-rich repetitive DNA sequences of (TTAGGG)n 
[62, 63].  Even though the majority of the telomere is double stranded, there is a single 
stranded 3 overhang that forms a loop as it folds back on the double stranded telomeric 
DNA and base pairs with a duplex region of telomeric repeats to form a t (telomere)-
loop [64].  Concurrently, a portion of the 5 to 3 strand along the length of the telomere 
is displaced to form the D (displacement)-loop [64].  The duplex region of the 
telomeric DNA framework allows the direct binding of two main telomeric proteins, 
telomeric repeat binding factors 1 and 2 (TRF1 and TRF2), which are important in 
telomere length regulation, integrity, and t-loop formation [65-67].  TRF1 functions in 
telomere length regulation, controlling the access of telomerase to the telomere termini 
[65], whereas TRF2 functions independently to protect telomeres from non-homologous 
end joining and activation of DNA repair or DNA damage response pathways [66, 68].  
Many protective functions are attributed to telomeres such as protecting the 
chromosomes ends from nuclease degradation, end-to-end fusion, ligation, and 
recombination [69].    In addition, a well-studied function attributed to telomeres is their 
ability to influence cellular replicative capacity of a cell, solving what is known as the 
end replication problem.   
 11 
The End Replication Problem and Telomere Hypothesis of Aging 
In the 1970's, as the mechanisms responsible for DNA replication were becoming 
better understood, it became clear that DNA polymerase could not fully synthesize the 3' 
end of linear DNA.  In 1972, Watson explained this as the end-replication problem [70].  
As depicted in Figure 1, DNA replication is a semi-conservative process in that the 
parental strands of DNA are separated and both are used as templates for the new 
daughter strands.  As the parental strands are unwinded by the helicases, a new daughter 
strand of DNA, leading strand, is formed in a 5 to 3 direction with an RNA primer 
attached to the parental strand of DNA to provide the DNA polymerase a starting point.  
Since DNA polymerase can only synthesize from the 5 to 3 direction, the 
complementary 3 to 5 daughter strand, lagging strand, is synthesized in small pieces 
called Okazaki fragments, each requiring an RNA primer, as the parental strand is 
unzipped.  As a consequence, DNA polymerase is unable to completely replicate the 3 
DNA end resulting in the loss of 50 to 200 base pairs of telomeric DNA with each 
successive round of replication [71, 72] (Figure 1).  Therefore, erosion of this non-coding 
DNA, the telomeres, acts as a mitotic clock, determining the number of replications 
allowable during a cellular lifespan [71, 72].  Upon reaching a critically shortened 
telomeric length, the cellular lifespan reaches its limit, known as the Hayflick Limit [73], 
and the shortened telomeres would then signal the cell to senesce in support of the 
telomere hypothesis of aging [74, 75]. 
As normal cells reach the limit of their lifespan through telomere shortening, most 
cells exit the cell cycle and enter a state called senescence [74].  Occassionally, a few 
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cells will bypass senescence and continue to proliferate.  At the end of this extended 
lifespan, cells experience genetic instability highlighted by chromosomal fusions and 
aneuploidy, then enter crisis [73, 76].  Escape from crisis is a spontaneous, rare event 
that gives rise to immortal cells, such as cancerous cells, capable of maintaining a stable 
telomeric length.  In order to escape from crisis, telomerase activation or reactivation is 
important to maintain a stable telomeric length (Figure 2). 
 
Figure 1 End Replication Problem [77] 
During DNA replication, leading and lagging DNA strands separate.  Using the parental 
strand as a template, DNA polymerase copies the leading strand in the 5 to 3 direction.  
Since DNA polymerase cannot synthesize in the 3 to 5 direction, the lagging strand is 
copied one segment at a time as the DNA strands unwind.  An RNA primer is laid down 
and the DNA polymerase extends this primer making an Okazaki fragment.  The primer 
is then removed and the DNA segments are ligated.  The lack of DNA at the very end of 
the 5 does not allow an Okazaki fragment to be ligated.  Therefore, the lagging strand is 
an incomplete replication of the parental 3 end. 
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Figure 2 Telomere Length in Relation to Senescence, Crisis, and 
Immortalization 
The Hayflick limit is the finite replicative capacity of normal somatic cells.  In order to 
bypass the Hayflick limit, telomerase has to be activated or reactivated.  Germ cells 
express telomerase until they undergo differentiation. In regenerative tissues, cells such 
as lymphocytes are capable of reactivating telomerase to enter a proliferative state.  In 
contrast, most somatic cells are telomerase negative and continuously experience 
telomere erosion with each round of replication.  Once cells reach a critically shortened 
telomere length, most cells lose their proliferative potential and senesce.  Nonetheless, a 
few cells overcome senescence and continue to proliferate with the risk of experiencing 
genetic instability and crisis.  When stabilization of telomere length is achieved by 
telomerase reactivation, cells spontaneously escape crisis allowing this cell population to 
become immortal.      
 
Clinical Relevance of Abnormal Telomeric Shortening 
Telomere shortening during aging occurs in a variety of human tissues and organs 
including dermal fibroblasts [78], peripheral blood cells [79], liver [80], and spleen [81].  
Most of these cells, tissues, and organs are mitotically active [81], except for the liver that 
shows very little mitotic activity indicating that there must be factors other than cell 
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division modulating the attrition of telomeres during aging [80].  In addition, the kinetics 
of telomere shortening during aging are not linear [82].  For instance, telomere shortening 
is accelerated in peripheral blood cells in young infants, plateaus in older children, and 
slowly decreases in adults [83].   
Accelerated telomeric loss is related to several clinical diseases including colitis 
ulcerosa [84], dyskeratosis congenital [85], and Fanconi anemia [86].  However, different 
mechanisms have been suggested as the cause of accelerated telomere shortening in these 
diseases.   
In colitis ulcerosa, it is suggested that elevated cell turnover leads to accelerated 
telomere shortening possibly limiting the regenerative capacity of affected organs [84].  
In the autosomal dominant form of dyskeratosis congenital, telomerase activity is 
inhibited because of an 821 bp deletion at the 3-end of the hTR gene resulting in 
accelerated telomeric loss [87].  Lastly, cells from patients with Fanconis anemia have 
high levels of intracellular radical oxygen species thought to induce telomere breaks, 
thereby shortening telomeres [86].  In conclusion, although the telomere represents a 
mechanism to regulate proliferation in normal cells, a mechanism that could counter or 
accelerate telomere shortening could modify replicative capacity.  
Telomerase 
Telomerase activity is associated with an increased proliferative capacity.  It can 
be detected in germline cells [88, 89] and the proliferative cells of renewal tissues such as 
hematopoietic cells, activated lymphocytes [90-93], and basal cells of the epidermis [94, 
95].  In addition, telomerase is detected in embryonic tissues, but its activity is repressed 
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as cells exit the cell cycle and differentiate [88, 96, 97].  Consequently, normal somatic 
cells do not typically express high levels of telomerase activity.   
Telomerase is the multi-subunit ribonucleoprotein (RNP) enzyme that elongates 
telomeric DNA at its 3 overhang [98, 99].  Telomerase consists of the human reverse 
transcriptase catalytic subunit (hTERT), the human RNA template (hTR) for telomeric 
sequence synthesis, and a number of telomerase associated proteins, which are important 
in the assembly of telomerase RNA into stable RNP.  hTR is a member of small nucleolar 
RNA molecules termed box H/ACA RNAs, which is an RNA motif with a consensus 
structure that includes a hairpin stem, a hinge sequence, a second hairpin stem and an 
ACA sequence, essential for precursor RNA 3 end processing and mature RNA 
accumulation [100].  The subunits hTR and hTERT associate to form a complex tetramer 
composed of two RNA subunits (hTR) and two catalytic subunits (hTERT) [101, 102].  
In addition to these core components, other proteins including telomerase-associated 
protein 1 (TEP1), heat shock proteins 90 (hsp90), molecular chaperones p23, and 
dyskerin are also included in the telomerase complex (Figure 3).  TEP1 is important in 
the stabilization and recruitment of hTR and hTERT in vitro [103]. The molecular 
chaperones p23 and hsp90 are essential for active telomerase assembly [104].  Dyskerin 
binds to the hTR H/ACA motif to stabilize the telomerase RNA [105].  Recently, EST1A 
and EST1B proteins have been shown to associate with telomeres and bind telomerase in 
vitro [106, 107].  Furthermore, overproduction of EST1A affects telomere length and 
capping by inducing anaphase bridges due to chromosome ends (Figure 3) [106, 107].    
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Figure 3 Telomerase-Associated Proteins [108] 
Telomerase is composed of the catalytic subunit hTERT and the RNA component hTR. 
The subunits associate to form a complex tetramer composed of two RNA subunits (hTR) 
and two catalytic subunits (hTERT). In addition to these core components other proteins 
including TEP1, p23, hsp90, and dyskerin have been associated with telomerase even 
though the exact functions of these proteins in telomerase formation and/or regulation are 
not completely understood.  Recently, homologs of the yeast Est1p protein, EST1A and 
EST1B have been shown to associate with telomeres and bind telomerase in vitro.  
 
Telomerase Confers Immortality and Chemotherapeutic Resistance 
Although telomerase re-activation is sufficient to extend cellular lifespan, hTERT 
expression is insufficient to trigger malignant transformation [109, 110].  However, 
immortalization contributes to increased susceptibility for cellular mutations eventually 
resulting in oncogenic transformation during prolonged cell proliferation.  In addition, 
telomerase activation has been shown to increase chemotherapeutic resistance consistent 
with poor prognosis in many tumors types including colon, breast, gastric, cervical, and 
uterine, and ovarian [111-114].  For instance, Faraoni et al  showed that telomerase 
activity in primary cultures of ovarian cancer cells was inversely related to 
chemosensitivity [114].  Also, Takahashi et al showed that all ovarian cancer patients 
responding to platinum therapy had low levels of telomerase whereas 50% of non-
responders demonstrated elevated telomerase activity [115].   When Shoup et al studied 
 17 
the effect of cisplatin sensitivity with concurrent treatment with telomerase inhibitors in 
vitro, they found that treatment of drug-resistant ovarian cancer cells, C13, with cisplatin 
and the telomerase inhibitor, 2-O-(2-methoxyethyl) RNA caused a 61% reduction in C13 
viability compared to controls and increased cisplatin-mediated cytotoxicity by 40% 
[116].   
Furthermore, studies have suggested that telomerase mediates chemoresistance by 
conferring resistance to apoptosis [117-123].  For instance, a recent study in our 
laboratory showed that introduction of hTERT expression into telomerase-negative 
immortalized ovarian surface epithelial (IOSE) cells was sufficient and specific to confer 
resistance to drug-induced cytotoxicity (Figure 4) [118].  Consequently, since telomerase 
re-activation is a crucial step for cellular immortalization and malignant transformation, 
inhibition of telomerase may act as a tumor-suppressive mechanism and have clinical 
utility as adjuvant therapy for enhanced chemosensitization. 
 
Figure 4  Telomerase Confers Resistance to Caspase-Mediated Apoptosis [118] 
Control IOSE cells, IOSE cells transfected with hTERT cDNA, and IOSE cells 
transfected with both hTERT cDNA and dominant negative (DN) hTERT cDNA were 
treated ± 1 µM staurosporine (STS) and examined for telomerase activity by PCR-ELISA 
(right panel) and assayed for activated caspase 3 by Western blot analysis using actin as a 
loading control (left panel).  Telomerase activity was expressed as the absorbance at 490 
nm ± S.E. 
  1      2      3      4      5      6
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Telomerase Therapeutics for Cancer 
Therapeutic opportunities exist in which cancer cells can be efficiently targeted 
by telomerase inhibitors, while normal telomerase-expressing cells, such as stem and 
germline cells, remain unaffected as a result of their longer telomere lengths and slower 
rates of cell division.  The most advanced telomerase therapeutic strategies include 
vaccines targeting telomerase, oligonucleotide-based therapeutics, and the use of a 
telomerase oncolytic virus.   
Since telomerase is over-expressed in nearly all cancers, it is considered an 
endogenous target for strategies using vaccines that boost the immune system to attack 
cancer cells.  Phase I and II clinical trial of patients with metastatic prostate cancer, 
demonstrated that cancer patients immune cells could be activated with a telomerase 
vaccine to kill their own cancer cells by using dendritic cells from patients blood, pulsed 
with hTERT RNA, then returned to the patients body where cytotoxic T-cells were 
instructed to kill tumor cells that expressed telomerase [124].  The results of this Phase I 
and II clinical trial showed that the immune responses of patients were strong as well as 
specific based on tests assessing the generation of telomerase-specific cytotoxic CD8+ T-
lymphocytes as well as CD4+ T-lymphocytes [124].  This study and similar studies [125-
129] have helped identify a clinical setting for testing immunotherapy against hTERT.   
Since the template region of hTR must be accessible to bind to the telomeric 
repeats, it has been suggested that the 11-base template region of telomerase RNA should 
be an excellent target for direct enzymatic inhibition of telomerase activity [130].  One 
agent in Phase I and II clinical trials in patients with chronic lymphocytic leukaemia is 
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GRN163L, a telomerase RNA template antagonist agent [131-133].  It contains a 
lapidated 13-mer thio-phosphoramidate that targets the hTR component of telomerase, 
preventing it from forming an active complex with hTERT [131-133].  GRN163L is one 
of the first generation of small-molecule telomerase inhibitors for the treatment of cancer.  
Current data suggest it has the potential to be a universal anticancer agent with minimal 
side effects.  
The third telomerase therapeutic with great potential is the vector-mediated 
approach of replicating oncolytic viruses to activate cell death (60-68).  Oncolytic 
viruses, which are tumor-selective viruses that mediate oncolytic effects on tumors, are 
genetically modified viruses engineered to replicate in and kill targeted cancer cells.  One 
oncolytic virus that has demonstrated a high degree of specificity and effectiveness in 
xenograft models is CG5757 [134].  This virus was generated by replacing the E1a and 
E1b endogenous promoters with promoters derived from the human E2F1 and the hTERT 
gene, respectively [134].  The E2F1 promoter is activated in retinoblastoma (Rb)-
defective tumor types, a pathway mutated in 85% of all cancers.  Likewise, telomerase is 
aberrantly expressed in 90% of tumors.  In vitro studies showed that expression of E1a 
and E1b genes was restricted to Rb-defective and hTERT-positive cancer cells and did 
not replicate in normal cells [134].  In addition, in vivo studies using the bladder cancer 
253J B-V mouse model showed the average tumor volume in animals treated with 4 
consecutive daily intratumoral injections of CG5757 decreased to 72% of baseline, 
compared to the control group that had an increase to 944% of baseline [134].  
Furthermore, 50% of treated animals had complete regression of the 253J B-V tumor 
 20 
xenografts [134].  Therefore, these data demonstrate that CG5757 has strong tumor 
selectivity and antitumor efficacy in cancers that are Rb-defective and hTERT 
(telomerase)-positive.   
Telomerase Regulation in Cancer Cells 
Although emerging telomerase-targeted therapy is a promising and novel 
approach to cancer therapeutics, many gaps still remain in our understanding of the 
complexities of the regulation of telomerase.  Therefore, it is important to understand its 
regulation in order to achieve optimal translational results.   
The hTERT gene is located on the distal arm of chromosome 5p (5p15.33) [135, 
136].  It consists of 16 exons and 15 introns across ~35 kb that is rich in GC content with 
no TATA and CAAT boxes, but contains binding sites for several transcription factors 
that may be involved in its regulation [137, 138].  Even though mutations are rare in this 
region, amplifications have been detected in some types of cancers, suggesting that 
increased copy number may be one mechanism that increases telomerase expression in 
human tumors [135, 139].   
The most common post-translational modification associated with telomerase 
regulation is phosphorylation.  Several kinases, including Akt and protein kinase Cα 
(PKCα) have been implicated in the regulation of telomerase [140-143].  Akt, a target of 
phosphotidyl inositol 3-kinase (PI3K), has been shown to activate telomerase in vitro by 
direct phosphorylation of hTERT [141].  Likewise, PKCα is capable of phosphorylating 
hTERT and consequently activating telomerase in breast cancer cells, while PKC 
inhibitors have an inhibitory effect on telomerase expression [140, 144].  On the other 
 21 
hand, phosphorylation of hTERT by c-Abl tyrosine kinase has been shown to 
downregulate telomerase activity [145].   
The hTERT promoter contains a number of regulatory sites including E-boxes, 
MT-box, Sp1, Myc, AP2 binding sites among others [137, 138, 146, 147].  The most 
studied of these transcription factors is c-Myc as a positive regulator of telomerase, while 
the c-Myc agonist, Mad, down regulates the hTERT expression [148-150].   
In addition, hTERT has been reported to have increased DNA methylation in its 
promoter region in hTERT-positive cancer cells and lack methylation in normal hTERT-
negative cells [151-155].  This pattern is inconsistent with observations that DNA 
methylation of promoter CpG islands is typically associated with gene silencing.  On the 
other hand, other reports of hTERT promoter DNA methylation suggest that methylation 
of the hTERT promoter is associated with gene silencing [152, 153, 156-158].  However, 
a recent study by Zinn et al showed that there is increased DNA methylation in the 
hTERT promoter of cancer cells, but hTERT maintains an unmethylated region around 
the transcription start site allowing the continued expression of hTERT in cancer cells 
[159].   
Characterization of the hTERT gene promoter has also revealed a number of 
potential binding sites for steroid hormone elements suggesting that steroid hormones 
may also be involved in regulating hTERT transcription [160-165].  One sex hormone 
that has been implicated in the development of a number of cancers, especially in breast 
and uterus, where it is a positive regulator of cell proliferation, is oestrogen [166, 167].  
In normal cells, oestrogen exerts profound effects on tissue growth, differentiation and 
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regeneration in a variety of tissues, including reproductive organs, bone, the 
cardiovascular system and the central nervous system [168-172].  It has been recently 
shown that under physiological conditions, there is a significant association between the 
levels of oestrogen and telomerase activity [173].  It has also been shown that oestrogen 
rapidly upregulates hTERT gene expression and telomerase activity in several oestrogen 
receptor (ER) α-positive cancer cell lines [160, 161].  Interestingly, mutation of the two 
c-Myc binding sites located within the proximal 181 bp promoter region completely 
abrogates oestrogen activation of telomerase activity even though the oestrogen response 
element (ERE) is located at the -2677 of the hTERT gene promoter [160].  These findings 
suggest that oestrogen may regulate hTERT gene transcription by cis and trans 
mechanisms involving c-Myc [174, 175].     
Telomerase Regulation by Growth Factors 
Growth factors play important roles in both positively and negatively regulating 
proliferation of a variety of cell types in tissue growth, differentiation, and tumorigenesis.  
Research efforts have shown that growth factors also regulate telomerase activity. 
Molecular regulation of telomerase activity by five growth factors have been 
extensively studied (Table 1).  Epidermal growth factor (EGF) plays an important role in 
cell proliferation of a variety of cells types by binding to the EGF receptor (EGFR), 
which stimulates several signal transduction pathways leading to the transcriptional 
activation of a number of growth-related genes and transcription factors including c-fos, 
c-jun, and Ets [176, 177].  This signaling pathway activation also plays an important role 
in the development of many solid tumors [178].  Treatment of EGFR-positive cancer 
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cells with EGF increases telomerase activity within 24 hours of exposure, which is 
preceded by a rapid increase in hTERT production, suggesting a transcriptional effect on 
the hTERT promoter via the Ras/MEK/ERK signaling pathway [176].  In addition, it has 
been shown that overexpression of the MAP kinase downstream transcription factor, Ets, 
enhances EGF stimulation of telomerase activity [176, 178].     
Fibroblast growth factor 2 (FGF2), also known as basic fibroblast growth factor 
(bFGF) is expressed in the embryonic central nervous system (CNS) [179] and it may be 
one of the main regulators of CNS development.  It has mitogenic action on cortical 
progenitor cells and it also regulates the generation of neurons and glia [180-182].     
Haïk et al showed that FGF2 dramatically upregulated telomerase activity in neural 
precursor cells through a possible post-transcriptional mechanism since hTERT mRNA 
levels were unaffected [183].  The study also proposed that FGF2-mediated upregulation 
of telomerase activity was mediated by the PI-3-kinase/Akt signaling pathway [183].   
A third growth factor that has been associated with cell development, lifespan, 
and aggressiveness of various tumor types is insulin-like growth factor (IGF) [184, 185].  
Studies have shown that IGF-1 stimulates telomerase activity, hTERT mRNA 
transcription, and protein expression in androgen-dependent and independent prostate 
cancer cell lines [184].  IGF-binding protein 2 (IGFBP-2) also stimulates telomerase 
activity in prostate cancer cells even though it acts as a growth inhibitor in normal 
prostate epithelial cells [186].  Interestingly, MAP kinase signaling is also involved in 
IGFBP-2-mediated telomerase activity, but not in IGF-1s [184, 186].  In addition, 
Akiyama et al showed that IGF-1 upregulated telomerase activity in multiple myeloma 
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cells without altering the hTERT protein expression via the phosphatidylinositol 3-
kinase (PI3k)/Akt/nuclear factor κB (NFκB) signaling pathway [187].  
Nerve growth factor (NGF) appears to be involved in the control of epithelial cell 
growth and differentiation [188].  Studies have shown that during NGF induction of cell 
proliferation in pheochromocytoma cells and prostate cancer cells, telomerase was 
significantly downregulated through the MAP kinase pathway [189-191].  
Transforming growth factor-β (TGF-β) uniquely regulates telomerase activity in a 
tumor-specific manner.  Treatment of human lung adenocarcinoma cells with TGF-β 
induces inhibition of telomerase and stimulation of the cancer cell senescence [192].  In 
addition, overexpression of TGF-β type II receptor (RII) in human colon carcinoma also 
leads to telomerase inhibition [193].  When RII is disrupted in human breast cancer cells, 
telomerase activity is increased [193].  The inhibition of telomerase activity by TGF-β 
correlates with decreased hTERT mRNA levels suggesting transcriptional repression of 
the hTERT promoter [138, 193].  However, studies of signaling pathways involved in 
TGF-β-mediated inhibition of telomerase activity have not yet been reported.   
The role of telomerase in cancer cell growth and survival is evident.  Although 
inhibition of telomerase may not result in immediate tumor death, the most rapidly 
proliferating tumors would undergo senescence eventually reducing patient tumor 
burden.  In addition, telomerase inhibitor treatments could be most beneficial when used 
in conjunction with current, traditional chemotherapeutic agents, tyrosine kinase 
inhibitors (RTKs) and monoclonal antibodies targeting angiogenesis.  Therefore, research 
studying telomerase regulation by growth factors important for cellular proliferation and 
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survival may produce novel tools specifically targeting the proliferative lifespan of 
tumorigenic cells. 
Table 1     Growth Factor-Mediated Telomerase Activity 
Growth 
Factor 
Effect on 
Telomerase Activity 
Possible 
Molecular Mediators 
EGF 
[176,178] 
Increases activity in 
telomerase-positive cells EGFR, ERK1/2, Ets 
FGF-2 
[183, 194, 
195] 
Increases telomerase in 
HUVECs and primary 
cortical cultures 
Akt/PI-3-kinase 
IGF-I 
[184, 187] 
Increases activity in prostate 
cancer cells 
Androgen receptor, Akt 
kinase 
IGFBP-2 
[186] 
Inhibits telomerase in 
normal prostate epithelial 
cells 
Increases activity in prostate 
cancer cells 
PI-3-kinase 
NGF 
[190, 191] 
Decreases telomerase in 
HUVECs, PC12 
pheochromocytoma cells, 
and prostate cancer cells 
MAPK 
TGF-β 
[192, 193] 
Decreases activity in colon 
and lung cancer cells 
RII disruption in breast 
cancer cells increases 
activity 
c-Myc, Smad proteins 
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Central Hypothesis 
Telomerase activity is regulated by growth factors in ovarian cancer cells. 
Specific Aims 
Since both VEGF and EGF regulate ovarian cancer cell growth and survival, this 
study examined whether these two growth factors could regulate telomerase activity in 
ovarian cancer cells.  Three specific aims were proposed to test this hypothesis:  
• Evaluate telomerase regulation by VEGF and its positive upstream regulator, 
LPA. 
• Since the nutraceutical, vitamin E, has been shown to degrade and suppress LPA 
activity, examine the potential of vitamin E to suppress telomerase activity by 
abrograting LPA-mediated telomerase activity.  
• Define EGF-mediated telomerase activity in ovarian cancer cells. 
 27 
 
Chapter II 
VEGF and LPA Induce Telomerase Activity in Ovarian Cancer Cells 
Abstract  
Both vascular endothelial growth factor (VEGF) and lysophosphatidic acid (LPA) 
are secreted by ovarian cancer cells and are known to promote cancer cell growth though 
the exact molecular mechanism(s) are not completely understood.  Since telomerase, a 
ribonucleoprotein expressed in 95% of ovarian cancer, plays an important role in cellular 
immortalization, growth, and tumor progression, it was examined whether telomerase is a 
molecular target of VEGF and LPA in ovarian cancer.  My experiments show that: (1) 
both VEGF and LPA upregulate telomerase activity; (2) LPA induction of telomerase 
activity is VEGF-dependent; (3) VEGF and LPA induction of telomerase activity is ERK 
1/2-dependent; and (4) Sp1 binding sites within the proximal 976- to 378-bp regions of 
the hTERT promoter are essential for VEGF- and LPA-induced hTERT promoter 
activity.  Consequently, these data show the novel finding that VEGF can regulate 
telomerase in non-endothelial cells and that telomerase appears to be a novel molecular 
target of LPA.   
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Introduction 
Ovarian cancer is the leading cause of gynecological cancer death in the United 
States [196].  Although a number of genetic changes have been identified in ovarian 
cancer, no single genetic alteration is common to all ovarian cancers [197, 198].  
However, telomerase activity is found in 90% of malignant tumors, including ovarian 
cancer [199].  Telomerase is a ribonucleoprotein that consists of an RNA (hTR) 
component, a reverse transcriptase (hTERT) component and associated proteins that 
elongates telomeric (TTAGGG)n DNA sequences de novo [89].  Both the protein catalytic 
hTERT and hTR subunits have been identified and cloned, and it is thought that the 
protein catalytic subunit, hTERT, is the limiting determinant of telomerase activity [102, 
200].  In the ovary, telomerase is absent in normal ovarian surface epithelium (OSE) and 
pre-malignant lesions, but tumor cells from both ascites fluid and ovarian carcinomas 
express telomerase activity [89, 201].   
Vascular endothelial growth factor (VEGF) is a homodimeric 34-42 kDa, heparin-
binding glycoprotein growth factor that plays a predominant pro-angiogenic role [202].  
Five common isoforms exist (VEGF121, VEGF144, VEGF165, VEGF189, VEGF206) as a 
result of alternate gene splicing [203, 204].  VEGF165 is the major isoform produced by 
several normal and tumor cells.  Once ligand bound, VEGFR-2, the major VEGF receptor 
involved in VEGF-mediated cell growth and angiogenesis, activates downstream 
signaling pathways, including mitogen activated protein kinase (MAPK) also known as 
extracellular signal-regulated kinase 1/2 (ERK 1/2) [205].  Recent reports indicated that a 
number of cancers including breast [206], prostate [207], leukemia [208], pancreatic 
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[209], and ovarian [210], express VEGF receptors, VEGFR-1, VEGFR-2 and neuropilin, 
that function in an autocrine loop to promote tumor cell growth, migration, and survival. 
Likewise, lysophosphatidic acid (LPA) is found in very high levels in plasma and 
ascites of ovarian cancer patients [211] and as a consequence it is considered a potential 
diagnostic marker for ovarian cancer [32].    LPA is the simplest glycerophospholipid that 
mediates several cellular responses, including smooth muscle cell contraction, regulation 
of cell proliferation, protection from apoptosis, modulation of chemotaxis and 
reproductive functions [212, 213].  It interacts with at least three specific cell surface G-
protein-coupled receptors of the endothelial differentiation gene (Edg) family, LPA1 
(Edg-2), LPA2 (Edg-4), and LPA3 (Edg-7) [214].  Ovarian cancer cells, particularly, 
express LPA receptors, LPA1 and LPA2 while the normal ovarian cells only express 
LPA 1 [215].  In addition, LPA stimulates VEGF production in ovarian cancer cells [216] 
suggesting that LPA can act in both a paracrine and autocrine manner for ovarian cancer 
tumor growth.   
Since VEGF and LPA are secreted by ovarian cancer cells and play important 
roles in cell growth and proliferation, VEGF regulation of telomerase activity and the 
possible contribution of LPA as an upstream regulator of VEGF-mediated telomerase 
activity in ovarian cancer were examined. My data show that both VEGF and LPA 
upregulate telomerase activity by ERK 1/2-dependent transcriptional activation of Sp1 
binding sites within the 976- to 378-bp hTERT promoter regions.  Furthermore, results 
show that LPA-mediated induction of telomerase activity is VEGF-dependent.  
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Materials and Methods 
Cell Lines and Tissue Culture 
Telomerase-positive ovarian carcinoma cell lines PA-1, SW 626, and one  non-
tumorigenic SV40 large-T antigen-transfected human ovarian surface epithelial (IOSE) 
cell line, FHIOSE 118, derived from normal ovarian surface epithelium were used [217].  
Cells were cultured in Medium 199/MDCB 105 (Sigma, St. Louis, MO) supplemented 
with 5% fetal bovine serum (FBS) (Hyclone, Logan, UT) and 10 µg/mL Gentamicin 
(GIBCO, NY).  The cells were incubated at 37ºC with 5% CO2 / 95% air.   
Treatment with VEGF, LPA, FGF-2, TNF-α, TGF-β, anti-hVEGF Antibody, CBO-
P11 and U0126 
Each cell line was grown in serum-free media for at least 18 hours prior to 
treatment with 25 to 150 ng/mL VEGF dissolved in 0.1% BSA (BioSource, Camarillo, 
CA), 20 µg/mL Oleoyl-L-α-lysophosphatidic acid sodium salt (LPA) dissolved in 1% 
BSA (Sigma Aldrich, St. Louis, MO), 20 ng/mL FGF-2 dissolved in 10 mM Tris pH 7.6 
(Sigma Aldrich, St. Louis, MO), 1 ng/mL TNF-α dissolved in 5 mM Tris pH 8.0 (Sigma 
Aldrich, St. Louis, MO), 5 ng/mL TGF-β dissolved in 4mM HCl containing 0.1% BSA 
(Sigma Aldrich, St. Louis, MO), 0.1 mg/mL anti-hVEGF Ab dissolved in PBS (R&D 
Systems, Minneapolis, MN), 1.3 µM VEGF receptor inhibitor, CBO-P11, dissolved in 
Milli-Q water (Calbiochem, La Jolla, CA), or 10 µg/mL U0126 MAPK inhibitor 
dissolved in methanol (Cell Signaling, Beverly, MA).  Cultures were harvested at various 
time intervals up to 24 hours.  
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Telomerase Assay 
To quantitatively detect changes in telomerase activity levels, cells were assayed 
for telomerase activity using the telomerase polymerase chain reaction-sandwich 
enzyme-linked immunosorbent assay (PCR-ELISA) following the manufacturers 
protocol (Roche, Indianapolis, IN) and as previously described [218].  Briefly, cells were 
washed with DPBS, trypsinized, and centrifuged at 500 g for 5 minutes.  Pellets were 
washed twice in DPBS, then resuspended in 150 µL of lysis buffer.  The cell pellets were 
kept on ice for 30 minutes and then centrifuged at 100,000 g for 60 minutes at 4°C.  
Supernates were then assayed using the Bio-Rad DC Protein Assay (Bio-Rad, Hercules, 
CA) to determine protein concentration following detergent solubilization according to 
manufacturers instructions.  To perform the telomerase PCR-ELISA within a linear 
range, all of the cells extracts equivalent to 3 µg of protein were used.  Following PCR-
ELISA, telomerase activity was detected using the ELx800 Universal Microplate Reader 
(Bio-Tek Instruments, Inc., Winooski, VT) and recorded as optical density ± S.E.   
RT-PCR 
To examine the contribution of transcriptional control of telomerase regulation by 
VEGF or LPA, Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) studies 
were performed as previously described [218].  Total RNA was collected using TRIzol 
reagent (Invitrogen, Carlsbad, CA).  One microgram total RNA, oligo(dT), and reverse 
transcriptase were used to generate single-strand cDNA for each sample.  The cDNA 
samples were amplified using the Perkin-Elmer (Palo Alto, CA) GeneAmp kit.  The 
hTERT primers used were hTERT-S (CGGAAGAGTGTCTGGAGCCAA) and hTERT-
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AS (GGATGAAGCGGAGTCTGGA) oligonucleotides (Sigma Genosys, The 
Woodlands, TX) and with β-actin primers Actin-S 
(CAGGTCATCACCATTGGCAATGAGC) and Actin-AS (GATGTCCACGT 
CACACTTCATGA) for an internal control.  The amplified products were then separated 
by electrophoresis on a 1% agarose, stained with 1X SyberGreen (FMC Bioproducts, 
Rocklan, ME) and analyzed with the Kodak EDAS 120 Digital Analysis System.  Net 
hTERT mRNA intensities from treated samples were normalized to their corresponding 
β-actin mRNA levels. 
Western Blot Analysis 
For Western blot analyses, cell lysates were prepared in CHAPS lysis buffer as 
previously described [219].  Protein concentrations of cell lysates were determined using 
the Bio-Rad Dc Protein Assay (Bio-Rad, Hercules, CA) in accordance to the 
manufacturers instructions.  Protein extracts (20 µg) were solubilized in SDS gel loading 
buffer (60 mM Tris base, 2% SDS, 10% glycerol, and 5% β-mercaptoethanol) and 
separated via 12.5% SDS-PAGE and electroblotted onto Hybond-ECL nitrocellulose 
membranes (Amersham Life Sciences, Piscataway, NJ) by wet transfer.  Immunoblotting 
was performed using antibodies against ERK 1/2 (1:1000) and phospho-ERK 1/2 
(1:1000; Cell Signaling, Beverly, MA), and Sp1 (1:1000) (Santa Cruz Biotechnology, 
Santa Cruz, CA).  β-actin (1:5000, Sigma Aldrich, St. Louis, MO) was used as loading 
control.  Blots were visualized using the ECL Western Blotting Analysis System 
(Amersham Pharmacia Biotech, Piscataway, NJ) according to the manufacturers 
instructions.  Blots were scanned and analyzed with Life Sciences GE Healthcare 
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ImageQuant image analysis software (GE Healthcare Bio-Sciences Corp., Piscataway, 
NJ). Values reported for target proteins were normalized to the blots' respective β-actin 
levels.  
Luciferase Reporter Assay  
To measure hTERT promoter activity, the full-length (pGL3-1375), and deleted 
hTERT promoter-luciferase constructs (pGL3-1175, -976, -776, -578, -378, -181) were 
used as previously described [220]. To determine whether the transcription factor, Sp1, 
was involved in VEGF- and LPA-induced telomerase activation, cells were transfected 
with 1 µM Sp1 siRNA (Santa Cruz Biotechnology, Santa Cruz, CA).  SW 626 cells were 
serum starved for 24 h and then transiently co-transfected with 3 µg of DNA and 1 U of 
β-galactosidase cDNA using Lipofectamine reagent (Invitrogen, Carlsbad, CA) in serum- 
and antibiotic-free media.  Cultures were replenished with serum 1h after transfection.  
Prior to collection, SW 626 cells were treated with ± VEGF (50 ng/mL for 4 hours), ± 
LPA (20 µg/mL for 24 hours), ± CBO-P11 (1.3 µM for 4 hours), and ± U0126 (10 µg/mL 
for 4 hours).  Expression of luciferase was measured 48 h after transfection using the 
Luciferase Assay System (Promega, Madison, WI) according to the manufacturers 
instructions.  At the time of collection, cells were microscopically observed to ensure cell 
viability with no signs of apoptosis using parallel cultures transfected with green 
fluorescent protein (GFP). Transcriptional activity was expressed as relative luciferase 
activity ± S.E., after normalization with β-galactosidase activity. 
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VEGF ELISA 
To measure VEGF production by cultured cells, equal amounts of conditioned 
media from cell lines treated with ± 20 µg/mL LPA for 24 hours were collected, 
centrifuged at 500 g for 5 minutes at room temperature to remove any cellular debris and 
the supernatants were frozen at -80°C until assayed using the quantitative sandwich 
enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, MN) 
according to the manufacturers instructions for VEGF165 levels.  The enzymatic reaction 
was detected at 450 nm using the ELx800 Universal Microplate Reader (Bio-Tek 
Instruments, Inc., Winooski, VT) and the results expressed as ρg/mL VEGF of triplicate 
experiments ± S.E. 
Statistical Analysis 
Samples for VEGF ELISA, telomerase PCR-ELISA, RT-PCR, and luciferase 
assays were run in triplicate, and the data were subjected to the Students t test for 
determination of statistical significance.  
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Results 
VEGF stimulates telomerase activity 
To determine whether VEGF mediated telomerase activity in ovarian cancer cells, 
time-dependent and dose-dependent assays were performed (Figures 5A and B).  
Telomerase activity was measured by PCR-ELISA for 0 to 24 hours following treatment 
with 0 to 150 ng of VEGF, respectively.  Cells were incubated in media containing 0.1% 
FBS for 24 hours prior to culturing them in the presence or absence of VEGF.  Figure 5A 
shows a gradual VEGF-mediated increase in telomerase activity peaking at four hours.  
Ovarian cancer cells PA-1 and SW 626 showed a 56% and a 63% increase in telomerase 
activity when treated for four hours, respectively.  Fifty ng/mL VEGF elicited greatest 
increase in telomerase activity in PA-1 (54%) and SW 626 (55%) cells (Figure 5B).  
Different dosages of VEGF or treatment intervals did not have any effect on telomerase 
activity in telomerase negative FHIOSE 118 cells serving as control (Figures 5A and B).   
To demonstrate specificity of VEGF for telomerase activity in ovarian cancer 
cells, cultures were either immuno-depleted of VEGF with anti-hVEGF antibody (Figure 
6A), treated with FGF-2, TNF-α or TGF-β (Figure 6A, inset) or treated with VEGF 
receptor inhibitor CBO-P11, which blocks the binding of VEGF165 to its receptors (IC50 = 
700 nM for VEGFR-1, 1.3 µM for VEGFR-2) (Figure 6B).  Immuno-depletion with anti-
hVEGF antibody in PA-1 and SW 626 cancer cells resulted in a moderate suppression of 
endogenous telomerase activity, 20% and 49%, respectively (Figure 6A).  However, 
immuno-depletion significantly suppressed VEGF-mediated activation of telomerase 
activity in PA-1 (47%) and in SW 626 (56%) cancer cell lines (Figure 6A).  In addition, 
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FGF-2, TNF-α and TGF-β failed to induce telomerase activity in either ovarian cell lines 
(Figure 6A, inset) indicating that not all growth factors generically increase telomerase 
activity in ovarian cancer cells.  Furthermore, CBO-P11 suppressed endogenous 
telomerase activity in PA-1 (20%) and SW 626 (36%) cells (Figure 6B).  CBO-P11 also 
inhibited VEGF-mediated activation of telomerase activity in both PA-1 (61%) and SW 
626 (71%) cells (Figure 6B).  Treatments with anti-hVEGF and CBO-P11 diluents (PBS 
and water) did not alter VEGF induction of telomerase activity.  In addition, telomerase-
negative FHIOSE 118 cells were unaffected by VEGF inhibition (Figures 6A and B) 
serving as control. 
VEGF induction of telomerase activity is transcription-dependent  
RT-PCR was employed to determine the relative levels of the telomerase catalytic 
hTERT mRNA in FHIOSE 118, SW 626, and PA-1 cells for VEGF-induced telomerase 
activity (Figure 7).  Cancer cell lines PA-1 and SW 626 demonstrated an increase of 67% 
and 55%, respectively, in relative levels of hTERT-mRNA transcript after 4-hour VEGF 
treatment when normalized to actin mRNA levels (Figure 7).  In contrast, VEGF failed to 
stimulate any hTERT transcription in the telomerase-negative FHIOSE 118 cells serving 
as control (Figure 7).   
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Figure 5 VEGF Induces Telomerase Activity in a Time- and Dose-Dependent 
Manner 
Telomerase activity was measured in cultured human ovarian FHIOSE 118, PA-1, and 
SW 626 cells treated with 50 ng/mL VEGF and examined for VEGF stimulation of 
telomerase at various time intervals up to 24 hours (A) and treated with 0 to 150 ng/mL 
of VEGF and collected at 4 hours (B).  * indicates the statistical significance of 
telomerase activity in PA-1 and SW 626 cells treated with 50 ng/mL VEGF for 4 hours 
compared to untreated controls.  Telomerase activity was measured by PCR-ELISA and 
expressed as mean optical density at 490 nm for triplicate samples ± S.E. 
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Figure 6 VEGF Induces Telomerase Activity 
To show specificity of VEGF to induce telomerase activity, cultures were 
immunodepleted of VEGF with anti-hVEGF antibody (A) or cells were treated with 
VEGF receptor inhibitor, CBO-P11 (B).  FHIOSE 118, PA-1, and SW 626 cells were 
treated with ± 50 ng/mL VEGF for 4 hours along with ± 0.1 mg/mL anti-hVEGF (A) ± 
1.3 µM CBO-P11 (B).  Samples were also treated with the diluents, PBS and water, 
serving as controls.  p values indicate statistical significance between VEGF treated cells 
vs. untreated cells (*), VEGF + anti-hVEGF or CBO-P11 vs. VEGF treated cells (**). 
FHIOSE 118 and SW 626 cell lines were also treated with either 20 ng/mL FGF-2, 1 
ng/mL TNF-α or 5 ng/mL TGF-β and examined for telomerase activity (A, inset).  
Telomerase activity was measured by PCR-ELISA and expressed as mean optical density 
at 490 nm for triplicate samples ± S.E.    
A
B 
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Figure 7 VEGF Increases hTERT Transcription Levels  
 FHIOSE 118, PA-1, and SW 626 cells were incubated ± 50 ng/mL VEGF for 0, 30 
minutes, 2 and 4 hours in triplicate and examined by RT-PCR for hTERT mRNA.  
Results are expressed as relative hTERT mRNA expression ± S.E. normalized to 
corresponding β-actin mRNA levels.  p values indicate the statistical significance of 
hTERT mRNA levels in PA-1 and SW 626 cells treated with 50 ng/mL VEGF at 4 hours 
compared to their untreated controls (*). 
 
VEGF-mediated telomerase activity is ERK 1/2-dependent 
In agreement with Pages et al [221], I found that VEGF increased ERK 1/2 
phosphorylation (Figure 8).  Western blot and densitometric analyses showed that VEGF 
increased ERK 1/2 phosphorylation by 50% and 61% in PA-1 and SW 626 ovarian 
cancer cells, respectively (Figure 8, inset).  Treatment with U0126 suppressed ERK 1/2 
phosphorylation and completely abrogated VEGF-mediated ERK 1/2 phosphorylation 
(Figure 8, inset).   
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Likewise, inhibition of ERK 1/2 by U0126 abrogated VEGF-mediated stimulation 
of telomerase activity to below endogenous levels (Figure 8) suggesting a role for MAPK 
in VEGF-mediated activation/regulation of telomerase activity.  Treatments with U0126 
diluent, methanol, did not alter VEGF induction of telomerase activity or VEGF-
mediated ERK 1/2 phosphorylation.  Telomerase-negative FHIOSE 118 cells remained 
telomerase negative and were unaffected by ERK 1/2 inhibition thereby serving as a 
negative control. 
 
Figure 8 VEGF Induction of Telomerase Activity is ERK 1/2-Dependent   
Cultures of FHIOSE 118, PA-1, and SW 626 were treated with ± 10µM U0126 and ± 50 
ng/mL VEGF for 4 hours.  Samples were also treated with U0126 diluent methanol 
serving as control.  Cells were then harvested and analyzed for telomerase activity by 
PCR-ELISA.  Results were expressed as mean optical density at 490 nm for triplicate 
samples ± S.E. p values indicate the statistical significance between VEGF treated cells 
vs. untreated controls (*) and VEGF + U0126 treated cells vs. VEGF treated cells (**).  
Western blot analysis (Inset) was performed to confirm VEGF-mediated phosphorylation 
of ERK 1/2 and U0126 inhibition of ERK 1/2 phosphorylation.  β-actin was used as the 
loading control.   
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Proximal 976- to 378-bp regions are required for induction of hTERT promoter 
activity by VEGF 
Since VEGF increased hTERT mRNA, using full length and deletion reporter 
constructs, reporter assays were performed to identify the promoter region(s) responsive 
to VEGF (Figure 9).  Compared to endogenous promoter activity (Figure 9), the full 
length promoter (PGL3-1375) was induced by VEGF by 42% (Figure 9).  However, 
VEGF induced maximal activity between 378-bp and 976-bp hTERT promoter regions, 
which were at least 4 times greater than that of the full length (PGL3-1375) hTERT 
promoter (Figure 9).  In contrast, VEGF failed to induce activity at the 1175-bp and 378-
bp hTERT promoter regions.  Interestingly, VEGF suppressed endogenous core promoter 
(PGL3-181) activity by 136%.  This suggests that VEGF positively targets transcription 
binding sequences within the 976- to 378-bp regions of the hTERT promoter. 
To confirm specificity of VEGF induction of the 378-bp to 976-bp hTERT 
promoter regions, reporter assays were also performed on SW 626 cells treated with 50 
ng/mL VEGF and either 1.3 µM VEGF receptor inhibitor CBO-P11 or 10 µg/mL ERK 
1/2 inhibitor U0126 (Figure 9).  VEGF failed to induce activity of the 1375-bp, 976-bp, 
776-bp, and 578-bp regions of the hTERT promoter when co-treated with CBO-P11 by 
67%, 42%, 92%, and 78%, respectively (Figure 9).  In addition, U0126 significantly 
suppressed VEGF-mediated induction of luciferase activity of the 1375-bp, 976-bp, 776-
bp, and 578-bp regions of the hTERT promoter by 65%, 25%, 91%, and 44%, 
respectively (Figure 9).  Furthermore, co-treatments with VEGF and either CBO-P11 or 
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U0126 alleviated VEGF-mediated suppression of 181-bp core promoter region by 
approximately 50% (Figure 9). 
LPA stimulates telomerase activity in ovarian cancer cells in a VEGF-dependent 
manner 
VEGF ELISA was performed on conditioned media from the ovarian cancer cell 
line, SW 626, and the IOSE cell line, FHIOSE 118 (Figure 10, inset).  In agreement with 
Hu et al [215], it was also observed that LPA increased VEGF secretion at least 1.5-fold 
in the ovarian cancer cell line, SW 626 and that LPA failed to promote VEGF production 
in the normal cell line, FHIOSE 118 (Figure 10, inset).   
To determine, then, whether telomerase activity was also a molecular target of 
LPA as an upstream regulator of VEGF, the effect of LPA on telomerase in ovarian cell 
lines FHIOSE 118, PA-1, and SW 626 was examined (Figure 11).  LPA (20 µg/mL) 
induced significant increases in telomerase activity in ovarian cancer cell lines PA-1 
(41%) and SW 626 (41%) (Figure 10).  However, LPA failed to stimulate telomerase 
activity in telomerase-negative FHIOSE 118 ovarian cells serving as control (Figure 10).  
Treatment with CBO-P11 suppressed 29% and 21% of endogenous telomerase activity in 
PA-1 and SW 626 ovarian cancer cell lines, respectively (Figure 10).  Furthermore, CBO-
P11 significantly suppressed LPA activation of telomerase activity in PA-1 (53%) and 
SW 626 (42%) cancer cell lines (Figure 10) suggesting that LPA-induced telomerase 
activity is VEGF-dependent. 
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Figure 10 LPA Induction of Telomerase Activity is VEGF-Dependent 
FHIOSE 118, PA-1, and SW 626 cells were treated with 20µg/mL LPA and examined for 
LPA stimulation of telomerase activity at 24 hours.  In addition, ovarian cancer cells were 
treated with ± 20 µg/mL LPA, ± 1.3 µM CBO-P11, harvested, and examined for 
telomerase activity by PCR-ELISA.  Results were expressed as mean optical density at 
490 nm for triplicate samples ± S.E.  p values indicate the statistical significance of LPA 
treated cells vs. untreated controls (*) and LPA + CBO-P11 treated cells vs. LPA treated 
cells (^).  (Inset) Enzyme-linked immunosorbent assay analysis of secreted VEGF protein 
concentrations in conditioned media of FHIOSE 118 and SW 626 cell lines treated with ± 
20 µg/mL LPA for 24 hours.  p values indicate the statistical significance of LPA treated 
SW 626 cells vs. untreated controls (*).   
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LPA-mediated telomerase activity is ERK 1/2-dependent 
In accordance to Kumagai et al [222], it was found that LPA increased ERK 1/2 
phosphorylation  (Figure 11, inset).  Western blot and densitometric analyses found that 
LPA increased ERK 1/2 phosphorylation by 63% and 33% in PA-1 and SW 626 cancer 
cells, respectively.  Treatment with U0126 suppressed ERK 1/2 phosphorylation and 
abrogated LPA-mediated ERK 1/2 phosphorylation (Figure 11, inset).  Similarly, LPA 
increased telomerase activity by 37% and 29% in PA-1 and SW 626 cancer cells, 
respectively.  As VEGF, inhibition of ERK 1/2 by U0126 abrogated LPA stimulation of 
telomerase activity to below endogenous levels (Figure 11) suggesting a role of ERK 1/2 
in LPA-mediated induction of telomerase activity.   
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Figure  11 LPA Induces Telomerase Activity via the ERK 1/2 Pathway 
FHIOSE 118, PA-1, and SW 626 cells were treated with ± 20 µg/mL LPA and ± 10 µM 
U0126 for 24 hours.  Cells were then harvested and analyzed for ERK 1/2 protein 
phosphorylation by Western blot (Inset) and telomerase activity by PCR-ELISA.  For 
Western blot analysis, β-actin was used as loading control.  p values indicate the 
statistical significance of LPA treated cells vs. untreated controls (*) and LPA + CBO-
P11 treated cells vs. LPA treated cells (**).  For telomerase analysis, results were 
expressed as mean optical density at 490 nm for triplicate samples ± S.E.   
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Proximal 976- to 378-bp regions are required for induction of hTERT promoter 
activity by LPA 
Since VEGF positively targeted transcription binding sequences within the 976- 
to 378-bp regions of the hTERT promoter to induce telomerase activity, additional 
reporter assays were performed to identify the promoter region responsive to LPA 
(Figures 12A and B).  Compared to endogenous promoter activity, full length promoter 
(PGL3-1375) was induced by LPA by 42% (Figure 12A).  Like VEGF, LPA induced 
maximal activity between 976- and 378-bp hTERT promoter regions, which were 2 times 
greater than that of the full length (PGL3-1375) hTERT promoter (Figures 12A and B).  
Interestingly, like VEGF, LPA also suppressed endogenous core promoter (PGL3-181) 
activity by 3-fold (Figure 12B).   
To confirm that LPA induction of telomerase was ERK 1/2- and VEGF-
dependent, reporter assays were performed on SW 626 cells treated with 20 µg/mL LPA 
and either 1.3 µM VEGF receptor inhibitor CBO-P11 or 10 µg/mL ERK 1/2 inhibitor 
U0126 (Figures 12A and B).  LPA failed to induce activity of the 1375-bp, 976-bp, 776-
bp, and 578-bp regions of the hTERT promoter when co-treated with CBO-P11 or U0126 
(Figure 12A) suggesting LPA induction of hTERT promoter activity is also ERK 1/2-
dependent (Figures 12A and B).  Furthermore, like VEGF, co-treatments with LPA and 
either CBO-P11 or U0126 alleviated LPA-mediated suppression of 181-bp core promoter 
region (Figures 12A and B). 
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Figure 13 VEGF- and LPA-Induced Telomerase Activity is Sp1-Dependent 
SW 626 cells were transfected with 1 µM Sp1 siRNA and treated with ± 50 ng/mL 
VEGF for 4 hours or ± 20 µg/mL LPA for 24 hours prior to collection.  Cells were then 
harvested and analyzed for Sp1 expression by Western blot (A, B insets) and telomerase 
activity by PCR-ELISA (A, B). For Western blot analyses, β-actin was used as loading 
control.  p values indicate the statistical significance of Sp1 tansfected cells vs. untreated 
controls (*), VEGF or LPA treated cells vs. untreated controls (~), and Sp1 transfected + 
VEGF or LPA treated cells vs. VEGF or LPA treated cells (^).  For telomerase analysis, 
results were expressed as mean optical density at 490 nm for triplicate samples ± S.E. 
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VEGF- and LPA-induced hTERT promoter activation is Sp1-dependent 
To identify whether Sp1 is a major transcription factor involved in VEGF- and 
LPA-induced hTERT activation, Western blot analyses (Figure 13), telomerase PCR-
ELISA analyses (Figure 13), and reporter assays (Figure 14) were performed using Sp1 
siRNA.  SW 626 cells were transfected with ± 1 µM Sp1 siRNA and treated with ± 50 
ng/mL VEGF or ± 20 µg/mL LPA.  Sp1 siRNA reduced endogenous Sp1 protein levels 
in SW 626 cells transfected with Sp1 siRNA (Figures 13A and B, insets, lane 2) and 
abolished VEGF- and LPA-mediated increased Sp1 levels (Figures 13A and B, insets, 
lane 4) compared to Sp1 siRNA untransfected controls (Figures 13A and B, insets, lanes 
1 and 3) as determined by Western blot analyses.  In addition, siRNA directed at Sp1 was 
sufficient to decrease endogenous telomerase activity by approximately 42% and 
decreased VEGF- and LPA-induced telomerase activity by 56% (Figures 13A and B).  
Furthermore, reporter assays using hTERT full length and deletion reporter constructs 
confirmed a role for Sp1 in VEGF- and LPA-induced telomerase activity (Figures 14A 
and B).  Compared to the endogenous promoter activity, the full length hTERT promoter 
was inhibited by Sp1 siRNA by 69% and VEGF- and LPA-induced full length hTERT 
promoter activities were inhibited by 42% and 45%, respectively (Figures 14A and B).  
Sp1 siRNA inhibited endogenous 976-bp hTERT promoter activity by 63% and VEGF- 
and LPA-induced promoter activity was reduced by 80% and 69%, respectively.  In 
contrast, the 776- to 378-bp hTERT promoter regions were not significantly affected by 
Sp1 siRNA (Figures 14A and B).  
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Discussion 
Telomerase regulation is complex involving transcriptional regulation [138], 
alternate mRNA splicing [223], and post-translational regulation by hTERT 
phosphorylation [175].  Recent studies have also shown that growth factors are crucially 
involved in regulating telomerase activity and hTERT reverse transcriptase gene 
expression.  For instance, in prostate cancer cells, insulin-like growth factor 1 (IGF-1) 
stimulates baseline telomerase activity up to 10-fold through hTERT phosphorylation and 
up-regulation of hTERT mRNA expression [184].   
The present experiments assessed telomerase as a potential molecular target of 
VEGF and its upstream regulator, LPA, in ovarian cancer cells.  Results show that both 
VEGF165 and LPA increased telomerase activity in telomerase-positive ovarian cancer 
cells, but not in telomerase-negative IOSE cells.  Inhibition of VEGF with either 
neutralizing antibodies or VEGF receptor inactivation suppressed VEGF- and LPA-
mediated induction of telomerase activity.  Therefore, these data demonstrate that VEGF 
and LPA are not limited to regulation of endothelial cell growth and survival, but also 
appears to regulate telomerase activity in ovarian cancer cells, thereby providing a 
plausible mechanism for the presence of their receptors in non-endothelial cells.  Both, 
VEGF and LPA, directly activated telomerase through up-regulation of hTERT 
transcription via the ERK 1/2 pathway and positively targeted transcription binding 
sequences within the 976- to 378-bp regions of the hTERT promoter.  Maximal baseline 
hTERT promoter activity was noted at 976- and 181-bp regions, possibly due to 
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endogenous growth factors and transcription factors present in the cells.  In contrast, 
maximal exogenous VEGF- and LPA-mediated transcriptional activity targeted to the 
976- to 378-bp regions of the hTERT promoter which contains putative binding sites for 
several transcription factors including Sp1 [224].  Sp1 silencing suggested that Sp1 is one 
major transcription factor involved in the VEGF- and LPA-induced transactivation of 
hTERT in ovarian cancer cells.  Since Sp1 silencing was not sufficient to completely 
abrogate VEGF- and LPA-induced telomerase activity, it is likely that additional 
transcription factors, possibly such as AP1 and AP2, binding within the 976- to 378-bp 
regions of the hTERT promoter also promote of VEGF- and LPA-mediated telomerase 
activity in ovarian cancer cells.   
Of interest binding sites for AP1 and AP2 are present in the 976- to 378-bp 
regions of the hTERT promoter.  In addition, p42/p44 MAP kinases activate the VEGF 
promoter at its -88 to -66 region where Sp1 and AP2 binding sites reside in endothelial 
cells [225].  Likewise, TGF-α also induces VEGF synthesis by AP2-mediated 
transcriptional activation in cervical cancer cells [226, 227].  Similarly, it has been 
suggested that LPA stimulation of ovarian tumor growth via VEGF occurs through 
activation of AP1 and Sp1 [215].  Since both Sp1 and AP2 play important roles in LPA 
and VEGF regulation, AP2 in conjunction with Sp1 may be important in LPA- and 
VEGF-mediated telomerase activity in ovarian cancer.   
While maximal telomerase induction was noted within the 976- to 378-bp regions 
of the hTERT promoter, VEGF and LPA suppressed activity of the core promoter region 
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(PGL3-181) of the hTERT promoter.  The core promoter region contains two E box 
binding factors and putative protein binding sites for transcription factors Sp1 and Ets 
[138].  However, E box binding proteins are known to heterodimerize with a variety of 
transcription factors with helix-loop-helix domains including Myc-related family 
members and Max-related family members [228].  c-Myc may form dimers with Max, 
which then binds to specific E-box binding sites to transactivate the hTERT promoter.  
However, c-Myc can also dimerize with Mad1 at the same binding site to suppress 
hTERT transcription [229].  Since the pro-angiogenic growth factor, transforming growth 
factor β1 (TGF-β1), has been shown to upregulate Mad1 expression resulting in a 
repression the hTERT promoter and telomerase activity [230], it is possible that VEGF 
and/or LPA, likewise, could favor c-Myc and Mad1 dimerization contributing to 
suppression in the hTERT core promoter.  Therefore, additional studies are needed to 
determine whether VEGF and LPA favor dimerization of Myc and Mad1 in this region of 
the promoter as mechanisms for core hTERT promoter repression.  However, net 
activation of the hTERT promoter by VEGF and LPA favor upregulation of telomerase 
activity.   
Most studies examining the relationship of VEGF-mediated telomerase activity 
have focused in endothelial cells [231-233].  However, little is known about the 
regulation of hTERT by VEGF in non-endothelial cells.  Zaccagnini et al showed that 
VEGF increased expression of mouse TERT and telomerase activity in skeletal muscles, 
satellite and endothelial cells contributing to tissue regeneration following hind limb 
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ischemia [234].  Several groups have reported a correlation between VEGF and hTERT 
mRNA expressions in breast carcinomas potentially contributing to the aggressive 
behavior of these tumors [235, 236].  My data, then, are the first to demonstrate not only 
the ability of VEGF and LPA to regulate telomerase in non-endothelial cells, but that 
telomerase may be a unique cellular target of both VEGF and LPA functions in ovarian 
cancer cells (Figure 15).  Consequently, the effectiveness of anti-angiogenic therapies 
may be two-fold, suppression of new blood vessel growth from local endothelial cells and 
inhibition of telomerase activity within tumor cells, and, therefore, may have important 
implications for the clinical management of tumors.  In summary, these data represent a 
paradigm shift in our previously held views of VEGF solely as a regulator of endothelial 
cell growth and survival and identify telomerase as a novel molecular target of LPA.  
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Figure 15 Proposed VEGF/LPA Regulation of Telomerase Activity in Ovarian 
Cancer Cells 
Delineation of a possible signaling pathway for induction of telomerase activity by VEGF 
as well as by its upstream regulator, LPA.  LPA, a potential biomarker for ovarian cancer, 
promotes VEGF production and secretion by ovarian cancer cells.  In turn, VEGF can act 
in a paracrine or autocrine manner to promote angiogenesis and telomerase activity, 
respectively.  The latter occurs in an ERK 1/2-dependent signaling manner targeting 
transcription factors, including Sp1, to the -976 to -378 hTERT promoter regions to 
enhance hTERT transcription and, subsequently, telomerase activity, essential for cancer 
cell survival.   
 
 
 
 
(Sp1) 
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Chapter III 
Vitamin E Suppresses LPA-Mediated Induction of Telomerase Activity  
in Ovarian Cancer Cells 
Abstract 
Dietary factors influence tumor formation and progression. Vitamin E is a dietary 
anti-oxidant capable of eliminating free radical damage, inducing apoptosis, and 
decreasing oncogene expression suggesting that vitamin E may be a strong candidate for 
cancer prevention and/or chemotherapeutic intervention.  In addition, vitamin E is known 
to degrade and suppress LPA activity.  Since I previously showed that lysophosphatidic 
acid (LPA) induces telomerase activity in human ovarian cancer cells, I studied whether 
vitamin E could indirectly suppress telomerase activity by abrogating LPA activity.  My 
data show that (1) vitamin E consistently abolished LPA-stimulated telomerase activity; 
(2) vitamin E suppressed endogenous telomerase activity in ovarian cancer cells; (3) 
vitamin E reduced hTERT mRNA transcript levels; (4) vitamin E reduced hTERT 
promoter activity maximally targeting the 976 to 578 bp promoter regions; and (5) 
vitamin E improved cisplatin-mediated cytotoxicity as evidenced by reduced cancer cell 
growth and increased caspase 3 activity.  These data suggest that, by suppressing 
 58 
telomerase activity, vitamin E may be an important protective agent against ovarian 
cancer cell growth as well as potentially effective therapeutic adjuvant.   
Introduction 
Ovarian cancer is the leading cause of gynecologic cancer death in women in the 
US.  It is the fourth leading cause of cancer death among women after lung, breast, and 
colorectal cancer [1] and is associated with a 1.7% lifetime risk [2].  It is estimated that 
22,220 new cases are diagnosed in the US annually and that 16,210 women die annually 
from this disease [1].  The one-year survival rate for ovarian cancer can be as high as 
79% and when diagnosed in an early stage the 5-year survival rate is almost 95% [1].  
However, when diagnosed at a later stage, the 5-year survival rate is generally no better 
than 35% [1].  Neither the survival rate nor the treatment for ovarian cancer has changed 
significantly for 30 years.  Optimal cytoreduction followed by platinum-based 
chemotherapy remains the mainstay of therapy in the management of advanced epithelial 
ovarian cancers [237]. However, while the response rate to primary chemotherapy can be 
as high as 76%, response rate is dramatically reduced after relapse of the disease [46].  
Platinum resistance, defined as disease recurrence less than six months from completion 
of therapy is an important prognosis predictor.  Patients with platinum-resistant tumors 
have a response rate of less than 10% when retreated with platinum compounds [46].  
Alternative options also have poor responses rates of 18-30% [238-240].   
The majority of ovarian cancers are sporadic in origin, but about 10% of all 
epithelial ovarian carcinomas are associated with a hereditary predisposition and are 
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characterized by an increased incidence and earlier onset of disease [198].  
Epidemiological studies suggest that, besides race [241] and familial history of breast or 
ovarian cancer [198], events associated with OSE traumatization may result in aberrant 
OSE growth leading to ovarian epithelial carcinogenesis [242].  Specifically, it has been 
suggested that incessant ovulation [243] causes rapid cycles of OSE division leading to 
errors in DNA replication and repair resulting in the inactivation and overexpression of 
tumor suppressor genes and oncogenes, respectively [244].  Thus, increased age, 
reproductive history (nulliparity), early menarche, late menopause, and fertility drug use 
increase the risk for ovarian cancer.  In contrast, suppression of ovulation by pregnancy, 
lactation or oral contraceptive use decreases the risk for ovarian cancer [245, 246].  
Lifestyle factors including dietary fat intake and smoking may also increase the risk for 
ovarian cancer while dietary intake of vitamins A, C, D, and E may protect against 
ovarian cancer [247, 248].   
Though a number of genetic abnormalities have been identified [197, 198], no 
single genetic alteration is common to all ovarian cancers.  Telomerase, a 
ribonucleoprotein that elongates telomeric (TTAGGG)n DNA repeats de novo [89], is 
expressed in over 90% of ovarian tumors [249] and plays an important role in 
immortalization and carcinogenesis [136].  In the ovary, telomerase activity is absent in 
normal OSE and pre-malignant lesions, while tumors cells from both ascites fluid and 
ovarian carcinomas express telomerase activity [250, 251].  Though telomerase 
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regulation is complex [138, 175, 223, 252, 253], telomerase activity in ovarian cancer 
also correlates with clinical stage and tumor aggressiveness [249, 250].   
While the primary function of telomerase is the maintenance of structural 
integrity at the linear chromosome ends, recent studies have shown an association 
between telomerase activity and increased chemotherapeutic resistance consistent with 
poor prognosis in ovarian cancers [254].  Telomerase appears to mediate its protective 
effect by conferring resistance to apoptosis [116, 120].  Likewise, I have shown that 
telomerase re-expression is associated with reduced caspase-mediated apoptosis and 
increased Bcl-2 expression in OSE cell lines [118]. 
LPA, the simplest glycerophospholipid, is present at high levels in plasma and 
ascites fluid from ovarian cancer patients and is thought to be a potential diagnostic 
marker for ovarian cancer [255]. Reduced levels of lipid phosphate phosphatase (LPP) 
and the production of aberrant forms of LPA may contribute to elevated LPA levels 
associated with ovarian cancer [256, 257]. LPA appears to assist ovarian cancer cell 
growth and invasion by numerous mechanisms including activation of cyclin D1 and 
metalloproteinases [258, 259]. In addition, ovarian cancer cells express LPA receptors, 
LPA1 (Edg2) and LPA2 (Edg4) [215].  
Previously, I have shown that LPA induces telomerase activity in human ovarian 
cancer cells.  Since it has been shown that vitamin E degrades and suppresses LPA 
activity, I sought to determine whether vitamin E inhibits LPA-mediated induction of 
telomerase activity in human ovarian cancer cells. 
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Materials and Methods 
Cell Culture 
The human ovarian cancer cell lines, C13, OV2008, PA-1, SW 626, A2780s, 
A2780cp, the telomerase-negative SV-40 large T antigen transfected normal ovarian 
surface epithelial (OSE) [217] cell lines FHIOSE 1816-575, FHIOSE 118, IOSE 80, and 
the telomerase-positive SV-40 large T antigen/hTERT transfected IOSE 80 + hTERT cell 
line [118, 260] maintained in our laboratory were used.  Cells were maintained in 
Medium 199/MDCB 105 (1:1) (Sigma-Aldrich, St. Louis, MO) supplemented with 5% 
fetal bovine serum (FBS) (Hyclone, Logan, UT) and 10 µg/mL gentamicin (GIBCO 
BRL, Grand Island, NY) in a humidified 5% CO2/95% air atmosphere.  Cells were 
treated with 0-100 IU d-alpha tocopheryl acetate (vitamin E) ± 20 µg/mL Oleoyl-L-α-
lysophosphatidic acid sodium salt (LPA) ± 25 µM of cisplatin (CDDP) (Sigma-Aldrich, 
St. Louis, MO) for 0 to 72 hours and then collected to perform the analyses described 
below.  
PCR-ELISA Telomerase Assay 
Telomerase activity was measured using the telomerase polymerase chain 
reaction enzyme-linked immunosorbent (PCR-ELISA) assay (Roche Applied Science, 
Indianapolis, IN) according to the manufacturers instructions and as performed 
previously [252, 253].  This assay has been demonstrated to be as sensitive as the 
radioactive telomere repeat amplification protocol (TRAP) assay [261].  Briefly, cells 
were washed with DPBS, trypsinized, counted, and centrifuged at 500 g for 5 minutes.  
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Pellets were washed twice in DPBS, then resuspended in 200 µL of lysis buffer  (10 mM 
Tris-HCl (pH 7.5), 1 mM MgCl2, 1 mM EGTA, 0.1 mM PMSF, 5 mM β-
mercaptoethanol, 0.5% CHAPS, 10% glycerol) and kept on ice for 30 minutes, after 
which time the lysates were centrifuged at 100,000 g for 60 minutes at 4°C.  Lysates 
were then assayed using the Bio-Rad DC Protein Assay (Bio-Rad, Hercules, CA) for the 
determination of protein concentration, according to the manufacturers instructions.  In 
order to perform the telomerase PCR-ELISA within a linear range, cell extracts 
equivalent to 3 µg of protein were used.  Following PCR-ELISA, telomerase activity was 
detected using the ELx800 Universal Microplate Reader (Bio-Tek Instruments, Inc., 
Winooski, VT) and recorded as absorbance units from triplicate samples ± S.E.   
RT-PCR 
To determine the contribution of vitamin E for transcriptional regulation of 
telomerase, RT-PCR studies were performed as described previously [252, 253].  Total 
RNA was collected using Trizol reagent (GIBCO BRL, Grand Island, NY).  One 
microgram total RNA, oligo(dT), and reverse transcriptase were used to generate single-
strand cDNA for each sample.  To ensure there was no DNA contamination, each sample 
for reverse transcription was prepared in duplicate, with the duplicate preparation lacking 
reverse transcriptase.  The cDNA samples were amplified using the Applied Biosystems 
GeneAmp kit (Foster City, CA).  The hTERT primers used were hTERT-S 
(CGGAAGAGTGTCTGGAGCAA) and hTERT-AS (GGATGAAGCGGAGTCTGGA) 
oligonucleotides (Sigma Genosys, The Woodlands, TX) with β-actin primers actin-S 
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(GGGAATTCAAAACTGGAACGGTGAAGG) and actin-AS 
(GGAAGCTTATCAAAGTCCTCGGCCACA) for an internal control.  PCR was 
performed for 33 cycles of 95°C for 20 seconds, 68°C for 40 seconds, and 72°C for 30 
seconds.  β-actin primers were added at cycle 16.  The amplified products were then 
separated by gel electrophoresis, stained with 1X SybrGreen (Cambrex Bioscience 
Rockland, Inc., Rockland, ME), and analyzed with the Kodak EDAS 120 Digital 
Analysis System.  Net hTERT mRNA intensities from triplicate treated samples were 
normalized to their corresponding β-actin mRNA levels and expressed as the average 
percent of control hTERT mRNA ± S.E.   
VEGF ELISA 
To measure VEGF production by cultured cells, equal amounts of conditioned 
media from cell lines treated with ± 20 µg/mL LPA ± 100 IU vitamin E for 24 hours were 
collected, centrifuged at 500 g for 5 minutes at room temperature to remove any cellular 
debris and the supernatants were frozen at -80°C until assayed using the quantitative 
sandwich enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Minneapolis, 
MN) according to the manufacturers instructions for VEGF165 levels.  The enzymatic 
reaction was detected at 450 nm using the ELx800 Universal Microplate Reader (Bio-Tek 
Instruments, Inc., Winooski, VT) and the results expressed as ρg/mL VEGF of triplicate 
experiments ± S.E. 
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SDS-PAGE and Western Blot Analysis  
SDS-PAGE and Western blot analyses were performed as described previously 
[252, 253].  Adherent cell populations were trypsinized, pelleted for 5 minutes at 500 g, 
and lysed in ice-cold lysis buffer (10 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 1 mM EGTA, 
0.1 mM PMSF, 5 mM β-mercaptoethanol, 0.5% CHAPS, 10% glycerol) for 30 minutes at 
4°C.  Lysates were then centrifuged at 100,000 g for 1 hour at 4°C.  Protein 
concentrations of the lysates were determined using the DC Protein Assay (Biorad, 
Hercules, CA) according to the manufacturers instructions.  Twenty micrograms of 
protein were added to 4X loading buffer (250 mM Tris pH 6.8, 8% SDS, 20% glycerol, 
0.012% bromophenol blue, 4% β-mercaptoethanol), heated to 95°C for 5 minutes, 
electrophoresed in 12.5% SDS-polyacrylamide gels, and transferred to nitrocellulose 
membrane (Amersham Piscataway, NJ).  All membranes were blocked for 1 hour with 
5% non-fat milk Tris Buffered Saline plus 0.1% Tween-20 (T-TBS) and incubated at 
least overnight at 4°C in primary antibody.  Polyclonal antibody to procaspase 3 (35 kDa) 
(1:1000), cleaved caspase-3 (19/17 kDa) (1:1000), and cleaved DFF45 (12 kDa) (1:1000) 
were purchased from Cell Signaling Technology, Inc. (Beverly, MA).  Membranes were 
incubated and developed according to Enhanced Chemiluminescent Protocol, according 
to manufacturers instructions (Amersham Piscataway, NJ).  After initial blotting, 
membranes were reprobed for β-actin (Sigma-Aldrich, St. Louis, MO) to ensure even 
loading.  Blots were scanned and analyzed with Life Sciences GE Healthcare 
ImageQuant image analysis software (GE Healthcare Bio-Sciences Corp., Piscataway, 
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NJ). Values reported for target proteins were normalized to the blots' respective β-actin 
levels.  Triplicate samples were expressed as average ± S.E.  
Luciferase Reporter Assay 
To measure hTERT promoter activity, the full-length (pGL3-1375), and deleted 
hTERT promoter-luciferase constructs (pGL3-1175, -976, -578) were used as previously 
described [220].  SW 626 cells were serum starved for 24 hours and then transiently co-
transfected with 3 µg of DNA and 1U of β-galactosidase cDNA using Lipofectamine 
reagent (Invitrogen, Carlsbad, CA) in serum- and antibiotic-free media.  Cultures were 
replenished with serum 1 hour after transfection.  Expression of luciferase was measured 
48 hours after transfection using the Luciferase Assay System (Promega, Madison, WI) 
according to manufacturers instructions.  At the time of collection, cells were 
microscopically observed to ensure cell viability with no signs of apoptosis and parallel 
cultures were transfected with green fluorescent protein (GFP) to ensure high transfection 
efficiency.  Transcriptional activity results from three independent studies were expressed 
as relative luciferase activity ± S.E., after normalization with β-galactosidase activity.  
MTS Assay for Cell Viability 
Cell growth was determined by the colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay which is 
based on the soluble formazan production by dehydrogenase enzymes found in 
metabolically active cells (Promega, Madison, USA).  Cells were trypsinized and 2 X 103 
cells were seeded in 96-well plates in 0.2 mL of growth media ± vitamin E (100 IU) ± 
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CDDP (25 µM).  Prior to collection, MTS/phenazine methosulfate (PMS) solution was 
added to each well and incubated at 37°C for 1 hour, at which time the absorbance at 490 
nm was determined using the ELx800 Universal Microplate Reader (Bio-Tek 
Instruments, Inc., Winooski, VT)  and the results expressed as mean absorbance of 
triplicate experiments ± S.E.   
Statistical Analysis 
Samples for telomerase PCR-ELISA, RT-PCR, luciferase, Western blot, and MTS 
assays were run in triplicate, and the data were subjected to the Students t test for 
determination of statistical significance between control and treated samples.   
Results 
Vitamin E suppresses telomerase activity 
To evaluate the effect of vitamin E on telomerase activity, the concentration- and 
time-dependent effects of vitamin E on telomerase activity in SW 626 ovarian cancer 
cells were initially determined.  PCR-ELISA showed vitamin E clearly decreased 
telomerase activity in human ovarian cancer cells.  Incubation of SW 626 cells with 
increasing concentrations of vitamin E (0-100 IU) for 24 hours resulted in a 
concentration-dependent down-regulation of telomerase activity with maximal 
telomerase inhibition (3-fold suppression of activity) when treated with 100 IU vitamin E 
(Figure 16A).  Likewise, vitamin E-mediated inhibition of telomerase was also time-
dependent.  Greatest suppression of telomerase by vitamin E occurred at 24 hours when 
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telomerase activity decreased by 55% (Figure 16B).  Therefore, cells were subsequently 
treated for 24 hours with 100 IU vitamin E in ensuing experiments.  A panel of additional 
ovarian cancer cell lines, PA-1, C13, OV2008, A2780s, and A2780cp, were treated with 
100 IU vitamin E for 24 hours to confirm vitamin E-mediated suppression of telomerase.  
Though there was no consistent vitamin E-mediated suppression of telomerase between 
drug sensitive parental cell lines (OV2008, A2780s) with their drug-resistant daughter 
cell lines (C13, A2780cp), each cell line showed a significant decrease in telomerase 
activity compared to their respective controls (C13 21%, OV2008 24%, A2780s 54%, 
and A2780cp 32%) (Figure 17), thereby substantiating that vitamin E suppresses 
telomerase activity in ovarian cancer cells.  In contrast, telomerase remained undetectable 
in telomerase-negative ovarian cell lines, FHIOSE 1816-575 and 118, when treated with 
vitamin E (Figure 17).   
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Figure 16 Vitamin E Suppression of Telomerase Activity is Dose- and Time-
Dependent 
Telomerase activity was assessed by PCR-ELISA in cultured human ovarian cancer SW 
626 cells treated with 0 to 100 IU vitamin E (A) for 0 to 24 hours (B).  * indicates the 
statistical significance of levels of telomerase activity in SW 626 cells treated with 100 
IU vitamin E for 24 hours compared to untreated controls.  Data from three independent 
experiments were quantified and expressed as mean absorbance at 490 nm ± S.E.   
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Figure 17 Vitamin E Suppresses Telomerase Activity in Human Ovarian Cancer 
Cells 
FHIOSE 1816-575, FHIOSE 118, SW 626, PA-1, OV2008, C13, A2780s, and A2780cp 
cells were treated ± 100 IU vitamin E for 24 hours, collected, and examined for 
telomerase activity by PCR-ELISA.  p values indicate statistically significant differences 
in telomerase activity between vitamin E treated cell lines and their untreated 
counterparts.  Data from three independent experiments were quantified and expressed as 
mean absorbance at 490 nm ± S.E.   
 
Vitamin E decreases hTERT RNA expression 
Since vitamin E significantly suppressed telomerase in SW 626 ovarian cancer 
cells, SW 626 ovarian cancer cells were used in subsequent experiments to determine the 
potential role of vitamin E on telomerase transcription.  RT-PCR was performed 
following incubation of SW 626 cells with 100 IU vitamin E for 0, 3, 18, and 24 hours to 
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determine whether vitamin E-mediated suppression of telomerase was transcription 
dependent (Figure 18).  Vitamin E steadily decreased hTERT mRNA levels with greatest 
vitamin E-mediated suppression resulting in almost 30% decreased hTERT mRNA 
expression at 18 hours (Figure 18) which preceded maximal inhibition of telomerase 
activity at 24 hours (Figure 17).  Actin mRNA levels remained unchanged throughout 
vitamin E treatments (Figure 18). 
 
Figure 18 Vitamin E-Mediated Suppression of Telomerase is Transcription-  
Dependent 
SW 626 cells were incubated ± 100 IU vitamin E for 0 to 24 hours, examined by RT-PCR 
for hTERT mRNA and expressed as net % control mRNA normalized to corresponding 
β-actin mRNA levels.  * indicates the statistical significance of hTERT mRNA levels in 
SW 626 cells treated with 100 IU vitamin E compared to untreated controls.   
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Vitamin E targets the -976 to -578 responsive regions of the hTERT promoter 
Reporter assays using full length and deleted hTERT reporter constructs were 
performed with SW 626 cells to identify the vitamin E-responsive elements in the hTERT 
promoter responsible for telomerase suppression.  Though vitamin E suppressed hTERT 
luciferase reporter activity in the full length (-1375) and the -1175 bp regions up to 47%, 
figure 19 shows the largest decrease in vitamin E-mediated luciferase reporter activity 
occurred within -976 to -578 bp hTERT promoter regions, with 89% and 64% inhibition, 
respectively.   
 
Figure 19 The 976- to 578-bp hTERT Promoter Regions are Required for 
Vitamin E Suppression of Telomerase Activity 
SW 626 cells were transfected with full length and deletion hTERT promoter luciferase 
constructs PGL3-1375, PGL3-1175, PGL3-976, PGL3-578 [220] as indicated along with 
pCMV-β-galactosidase expression vector and treated ± 100 IU vitamin E for 24 hours.  
Luciferase reporter activity was normalized by dividing luciferase activity with β-
galactosidase.  Results are expressed as the mean luciferase activity ± S.E. from triplicate 
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samples and p values indicate statistical differences between luciferase assays in SW 626 
cells with and without vitamin E treatment. 
Vitamin E suppresses LPA-induced telomerase activity in ovarian cancer cells 
Vitamin E has been shown to degrade and suppress LPA activity [262].  While I 
did not directly measure LPA levels following vitamin E treatment, VEGF ELISA was 
performed on conditioned media from SW 626 cancer cells treated with ± vitamin E and 
± LPA to indirectly demonstrate the ability of vitamin E to suppress LPA activation of its 
downstream target, VEGF (Figure 20A).  LPA increased VEGF secretion at least 1.5-fold 
in the SW 626 cells (Figure 20A).  In contrast, vitamin E suppressed VEGF endogenous 
levels by 22%.  In addition, vitamin E abrogated LPA-increased VEGF secretion by 62% 
(Figure 20A).  To study whether vitamin E could similarly suppress telomerase activity 
by abrogating LPA-mediated telomerase activity,  ovarian cell lines FHIOSE 118, PA-1, 
SW 626, cisplatin-sensitive OV2008, cisplatin-resistant daughter cell line C13, cisplatin-
sensitive A2780s, and cisplatin-resistant daughter cell line A2780cp were treated with ± 
20 µg/mL LPA and ± 100 IU vitamin E for 24 hours, and examined for telomerase 
activity (Figure 20B).  When ovarian cancer cells were treated with vitamin E alone, 
vitamin E suppressed endogenous telomerase activity in all ovarian cancer cell lines 
tested (PA-1 42%, SW 626 38%, OV2008 13%, C13 34%, A2780s 34%, A2780CP 38%) 
(Figure 20B).  In addition, when co-treated with LPA, vitamin E consistently abolished 
LPA induction of telomerase activity in all ovarian cancer cell lines tested (PA-1 63%, 
SW 626 60%, OV2008 59%, C13 58%, A2780s 66%, A2780CP 64%) (Figure 20B).  In 
contrast, LPA and vitamin E failed to either induce or suppress telomerase activity in 
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telomerase-negative ovarian cell line, FHIOSE 118 serving as control (Figure 20B).  
These findings show vitamin E suppresses LPA-mediated telomerase activity in human 
ovarian cancer cells.   
To confirm vitamin E abrogated LPA-mediated induction of telomerase activity, 
reporter assays were performed on SW 626 cells treated with 20 µg/mL LPA and 100 IU 
vitamin E.  Figure 21 shows that LPA failed to induce activity of the 976-bp and 578-bp 
of the hTERT promoter when co-treated with vitamin E (Figure 21).  
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Figure 20 Vitamin E Suppresses LPA-Mediated Telomerase Activity 
(A) Enzyme-linked immunosorbent assay analysis of secreted VEGF protein 
concentrations in conditioned media of SW 626 cells treated with ± 20 µg/mL LPA ± 100 
IU vitamin E for 24 hours.  (B) Ovarian cell lines, FHIOSE 118, PA-1, SW 626, 
OV2008, C13, A2780s, and A2780cp were treated with 0.1% FBS, ± 100 IU vitamin E 
and ± 20 µg/mL LPA for 24 hours and assessed for telomerase activity by PCR-ELISA.  
p values indicate statistically significant differences in telomerase activity between LPA 
treated cell lines vs. vitamin E + LPA treated cell lines.  Data from three independent 
experiments were quantified and expressed as mean absorbance at 490 nm ± S.E.  p 
values indicate the statistical significance of LPA treated cells vs. untreated control (*), 
vitamin E treated cells vs. untreated control (~), and LPA + vitamin E treated cells vs. 
LPA treated cells (^). 
A 
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Figure 22 Vitamin E Increases Chemotherapeutic Sensitivity in Ovarian Cancer 
Cells 
Cisplatin-sensitive, OV2008 (A, B, C) and its daughter cisplatin-resistant, C13 (D, E, F), 
ovarian cancer cells were treated ± 100 IU vitamin E ± 25 µM CDDP and were subjected 
to MTS assays (A,D), Western immunoblot (B, E), and PCR ELISA for telomerase (C, 
F).  A, D) Measurement of cell growth by MTS was expressed as average absorbance  
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Figure 22 (Continued) Vitamin E Increases Chemotherapeutic Sensitivity in 
Ovarian Cancer Cells 
from triplicate samples at 490 nm ± S.E.  *, ** and *** indicate statistical differences 
between control vs. CDDP treated cells, control vs. vitamin E and CDDP treated cells, 
and CDDP treated cells vs. vitamin E and CDDP treated cells at 24 hours, respectively.  
B, E) Parallel OV2008 and C13 cultures were treated ± 100 IU vitamin E ± 25 µM 
CDDP for 24 hours and subjected to SDS-PAGE and Western immunoblot for caspase 3 
cleavage.  Untreated controls (lane 1), cells treated with CDDP (lane 2), cells treated with 
vitamin E (lane 3), and cells treated with both vitamin E and CDDP (lane 4) are 
indicated. Actin served as a loading control for Western immunoblot analyses.  
Telomerase activity was measured by PCR-ELISA following treatment ± 100 IU vitamin 
E ± 25 µM CDDP for 24 hours (B, E) and telomerase activity was expressed as mean 
absorbance from triplicate samples at 490 nm ± S.E. with p values indicating differences 
between vitamin E treated and untreated control samples.   
 
 
Vitamin E enhances cisplatin-mediated cytotoxicity in ovarian cancer cells 
 
Anderson et al have shown that a vitamin E derivative, 2,5,7,8-tetramethyl-2R-
(4R,8R,12-trimethyltridecyl)-chroman-6-yloxyacetic acid (α-TEA) in combination with 
cisplatin reduced tumor burden of cisplatin-resistant human ovarian cancer cells 
xenografted into immune compromised nude mice.  To determine the potential 
therapeutic benefit of vitamin E-mediated telomerase inhibition for platinum-mediated 
cytotoxicity, MTS, Western immunoblot, and telomerase PCR-ELISA assays were 
performed in the cisplatin-sensitive cancer cell line, OV2008, and its cisplatin-resistant 
daughter cell line, C13, following treatment ± 25 µM CDDP ± 100 IU vitamin E for up to 
72 hours (Figure 22).  Significant cisplatin-induced growth inhibition occurred by 24 
hours when OV2008 cell growth decreased 60% in CDDP treated OV2008 cells 
compared to the untreated controls (Figure 22A).  OV2008 cell growth decreased by 68% 
by 24 hours when treated with CDDP + vitamin E suggesting that vitamin E increased 
platinum-mediated cytotoxicity by 8%.  To determine whether apoptosis was induced, 
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SDS-PAGE analyses for procaspase 3, cleaved caspase 3, and cleaved DFF45 in OV2008 
cells treated ± vitamin E ± CDDP for 24 hours were performed (Figure 22B).  Treatments 
with CDDP + vitamin E stimulated caspase 3 activation by 40% when compared to cells 
treated with CDDP alone as seen by the reduction of procaspase 3 (35 kDa) expression 
and an increase in caspase 3 activation (19/17 kDa) as determined by Western blot and 
densitometry analyses (Figure 22B).  Caspase 3 activation leads to DNA fragmentation 
factor (DFF) 45 cleavage into 24- and 12-kDa fragments releasing DFF40 allowing 
translocation to the nucleus and cleaving genomic DNA, a key step in apoptosis [263, 
264].  Western blot analyses against cleaved DFF45 (12 kDa) showed an increase in 
DFF45 activation in CDDP treated cells and CDDP + vitamin E treated by 72% and 76%, 
respectively, as determined by densitometry analyses.  However, additional MTS assays 
in which OV2008 and C13 cells were treated with 20, 40, 60, 100, and 200 IU vitamin E 
± CDDP for 0 to 72 hours did not show a significant additive effect of vitamin E for 
CDDP-mediated cytotoxicity (data not shown).  In addition, vitamin E significantly 
suppressed telomerase activity compared to untreated controls regardless of the presence 
of CDDP and CDDP alone did not dramatically alter telomerase levels (Figure 22C).   
As expected for drug resistant cells, treatment of C13 ovarian cancer cells with 
CDDP alone suppressed cell growth to a lesser extent (33% at 24 hours) than OV2008 
cells (Figure 22D).  C13 cell growth decreased by 52% at 24 hours when treated with 
CDDP + vitamin E suggesting that vitamin E increased platinum-mediated cytotoxicity 
by approximately 20%.  To determine whether apoptosis was induced, SDS-PAGE 
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analyses for procaspase 3, cleaved caspase 3, and cleaved DFF45 in C13 cells treated ± 
vitamin E ± CDDP for 24 hours were performed (Figure 22E).   Procaspase 3 activity 
was decreased in CDDP and CDDP + vitamin E treated cells by 43% and 34%, 
respectively, compared to untreated cells as determined by densitometry.  Decrease in 
procaspase 3 activity lead to increase in cleaved caspase 3 in CDDP and CDDP + vitamin 
E treated cells by 76% and 74%, respectively, compared to untreated cells.  Cleaved 
DFF45 activity was also elevated in CDDP and CDDP + vitamin E treated cells by 69% 
and 70%, respectively, compared to untreated cells.  Similarly, vitamin E significantly 
suppressed telomerase activity in C13 cells compared to untreated controls regardless of 
the presence of CDDP.  In addition, CDDP alone did not dramatically alter telomerase 
levels (Figure 22F).   
To determine if vitamin E targeted telomerase for increased platinum-mediated 
cytotoxicity, telomerase-negative IOSE 80 and telomerase-positive IOSE 80 + hTERT 
cells were analyzed by MTS, Western immunoblot, and telomerase PCR-ELISA assays 
as above following treatment ± 25 µM CDDP ± vitamin E for up to 72 hours (Figure 23).  
Maximal cisplatin-induced growth inhibition occurred by 24 hours when cell growth 
decreased 66% in CDDP treated IOSE 80 compared to their untreated controls (Figure 
23A).  IOSE 80 cell growth only decreased by 48% by 24 hours in IOSE 80 treated with 
CDDP + vitamin E for 24 hours suggesting that vitamin E protected telomerase-negative 
cells against cisplatin-induced cytotoxicity by approximately 20%.  To determine 
whether apoptosis was induced, SDS-PAGE analyses for procaspase 3, cleaved caspase 
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3, and cleaved DFF45 in C13 cells treated ± vitamin E ± CDDP for 24 hours were 
performed (Figure 23B).   Procaspase 3 activity was decreased in CDDP and CDDP + 
vitamin E treated cells by 43% and 34%, respectively, compared to untreated cells as 
determined by densitometry.  Decrease in procaspase 3 activity lead to increase in 
cleaved caspase 3 in CDDP and CDDP + vitamin E treated cells by 75%, compared to 
untreated cells.  Cleaved DFF45 activity was also elevated in CDDP and CDDP + 
vitamin E treated cells by 70% and 69%, respectively, compared to untreated cells.  
Lastly, IOSE 80 cells remained telomerase negative regardless of vitamin E or CDDP 
treatment (Figure 23C).   
In contrast, cell growth decreased 43% in IOSE 80 + hTERT cells treated with 
CDDP and additionally to 54% when cells were treated with CDDP + vitamin E for 24 
hours (Figure 23D).  Similarly, IOSE 80 + hTERT cells treated with CDDP showed a 
marked increase in caspase 3 activation compared to their controls (Figure 23E).  Unlike 
IOSE 80 cells, however, IOSE 80 + hTERT cells treated with the combination of CDDP 
+ vitamin E demonstrated a higher increase in activation of caspase 3 (80%) as 
determined by densitometry compared to the IOSE 80 + hTERT cell treated with CDDP 
alone (69%) (Figure 23E).  In addition, cleaved DFF45 activity was higher in CDDP + 
vitamin E treated cells (78%) than CDDP treated cells alone (74%).  Lastly, vitamin E 
reduced telomerase activity 3-fold in IOSE 80 + hTERT cells while a 4-fold decrease in 
telomerase activity was observed when IOSE 80 + hTERT cells were treated with CDDP 
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+ vitamin E (Figure 23F) corroborating the effects of these two agents on telomerase-
positive ovarian cell lines. 
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Figure 23 Vitamin E May Protect Telomerase-Negative Cells from Cisplatin-
Mediated Cytotoxicity 
 Telomerase-negative, IOSE 80 (A, B, C) and telomerase-positive, IOSE 80 + hTERT (D, 
E, F) cells were treated ± 100 IU vitamin E ± 25 µM CDDP and were subjected to MTS 
assays (A, D),  
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Figure 23 (Continued) Vitamin E May Protect Telomerase-Negative Cells from 
Cisplatin-Mediated Cytotoxicity 
Western immunoblot (B, E) and PCR-ELISA for telomerase (C, F) as described in the 
Materials and Methods section. Measurement of cell growth by MTS was expressed as 
average absorbance from triplicate samples at 490 nm ± S.E.  *, **, and *** indicate 
statistical differences between control vs. CDDP treated cells, control vs. vitamin E and 
CDDP treated cells, and CDDP treated cells vs. vitamin E and CDDP treated cells at 24 
hours, respectively.  Parallel IOSE 80 and IOSE 80 + hTERT cultures were subjected to 
SDS-PAGE and Western immunoblot for caspase 3 cleavage with untreated controls 
(lane 1), cells treated with CDDP (lane 2), cells treated with vitamin E (lane 3) and cells 
treated with both vitamin E and CDDP (lane 4) are indicated. Actin served as a loading 
control for Western immunoblot analyses.  Telomerase activity was measured by PCR-
ELISA (C, F) following treatment ± 100 IU vitamin E ± 25 µM CDDP for 24 hours (B, 
E).  Telomerase activity was expressed as mean absorbance from triplicate samples at 
490 nm ± S.E. with p values indicating differences between vitamin E treated and 
untreated control samples. 
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Discussion 
Vitamin E, the common term for compounds that demonstrate tocopherol and 
tocotrienol activities, has long been recognized as a dietary anti-oxidant.  However, in 
addition to eliminating free radical damage, vitamin E functions in cell signaling 
pathways, regulation of oncogene expression, and cancer prevention [265].  Regarding 
the latter, epidemiological studies show that diets rich in vitamin E or dietary 
supplementation of vitamin E are associated with a reduced risk of ovarian cancer [266-
269].  Clinically, vitamin E can alleviate chemotherapy-induced side effects and improve 
chemotherapeutic efficacy. Argyriou et al demonstrated that dietary vitamin E 
supplementation significantly reduced cisplatin and paclitaxel-induced neurotoxicity 
[270].  Further, dietary administration of vitamin E to ovarian cancer patients between 
periods of chemotherapeutic treatment reduced cathepsin activity, thereby reducing 
extracellular matrix proteolysis important for tumor invasion and metastasis [271].  
Preliminary case reports also indicate that high dose oral vitamin E therapy during first-
line platinum/paclitaxel chemotherapy results in normalization of CA125 levels after first 
cycle chemotherapy [272].  Likewise, dietary vitamin E has been associated with 
increased survival in patients with ovarian cancer [273].  Lastly, Hahn et al [274] 
observed a 4.8 fold reduction of lung tumor metastasis in mice model of mammary 
cancer when the mice were fed mouse food with alpha-TEA, a synthetic vitamin E 
analog.   
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There is growing evidence that the physiological function of vitamin E in cancer 
extends beyond an anti-oxidant to include regulation of gene transcription and enzymatic 
activities [275].  Notably, vitamin E can induce apoptosis by inhibition of protein kinase 
C activity [275] or increased sensitivity to TRAIL [276].  In addition, vitamin E inhibits 
cancer cell invasiveness by decreasing levels of matrix metalloproteinases and can inhibit 
cell cycle progression by downregulation of cyclins D1 and E [277].  Since telomerase 
plays an important role in cellular immortalization and tumor progression, these 
experiments focused on the potential for vitamin E to alter telomerase activity.  Novel 
findings are reported that vitamin E not only inhibited endogenous telomerase activity in 
telomerase-positive OSE or ovarian cancer cells while telomerase-negative OSE cells 
remain unaffected, but it also abrogated LPA-mediated increase in telomerase activity in 
ovarian cancer cells.  Further, vitamin E-mediated suppression of telomerase was 
transcription dependent as noted by reduced hTERT mRNA, but not actin mRNA levels 
following treatment with vitamin E suggesting that vitamin E did not decrease gene 
expression globally.  The ability of vitamin E to suppress only 30% of hTERT mRNA 
levels during 18 hours of vitamin E treatment may reflect the characteristically long half-
life of hTERT mRNA though maximal vitamin E-mediated suppression of hTERT 
mRNA levels preceded greatest inhibition of telomerase activity.   
Suppression of hTERT transcription by vitamin E appeared to maximally target 
the -976 to -578 bp regions of the hTERT promoter.  This finding is in agreement with 
Fujimoto et al who identified MZF-2 as a negative regulator of hTERT transcription 
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within the -776 and -378 bp hTERT promoter regions resulting in transcriptional hTERT 
silencing [278].  In addition, p73, CTCF and USF have also been shown to negatively 
regulate telomerase transcriptional activity [279-281].  Interestingly, binding sites for 
MZF-2 and CTFC are present in the -976 and -578 hTERT promoter regions where 
vitamin E appeared to maximally suppress hTERT transcription in the present study.  
Given that the hTERT promoter has been cloned and several potential transcription factor 
binding sites noted [137], the relatively small suppression of hTERT promoter activity 
found in both the full length 1375 and 1175 deleted promoter constructs following 
vitamin E treatments may reflect the presence of both negative and positive hTERT 
transcription regulators present within these regions of the hTERT promoter excluded 
from the -976 to -578 bp regions.  Clearly, then, further studies are warranted to identify 
the transcription factors that bind to the 976- to 578-bp regions of the hTERT promoter 
responsible for vitamin E-mediated inhibition of telomerase.   
Of clinical significance, these experiments found that vitamin E suppresses LPA-
mediated telomerase activity in ovarian cancer cells (Figure 24).  Since LPA is found in 
very high levels in plasma and ascites of ovarian cancer patients [211] and it seems to 
facilitate ovarian cancer cell growth and invasion [212, 213], it is important to know that 
vitamin E could be an agent that inhibits LPA and its downstream targets.  In agreement 
with others [282], these experiments found that vitamin E increased cisplatin-mediated 
cytotoxicity in ovarian cancer cells in culture.  Though prevailing clinical thought 
opposes the use of anti-oxidants fearing that vitamin E may protect cancer cells from free 
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radical damage, Jha et al showed that a number of cancer cell lines, including ovarian 
cancer, treated with vitamin E and X-irradiation were sufficiently growth arrested to 
warrant consideration of vitamin E for potential therapeutic benefit [283].  In agreement, 
these experiments show that vitamin E decreased telomerase activity and increased 
cisplatin-mediated cytotoxicity in telomerase-positive ovarian cells.  In addition, it was 
shown that vitamin E may act as a protective agent in normal, telomerase-negative, 
ovarian cells against cisplatin-mediated cytotoxicity which may help alleviate the 
apprehension for using vitamin E therapeutically.  Though in vivo testing and clinical 
studies need to be performed to further evaluate the clinical efficacy of vitamin E for 
chemotherapeutic efficacy, results show that, by targeting telomerase, supplemental 
vitamin E may be a useful adjuvant for prevention of ovarian cancer and/or improved 
chemosensitivity, which could reduce the mortality of a disease that kills thousands of 
women annually. 
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Figure 24 Schematic Representation of VEGF-Induced Telomerase Activity and 
Vitamin E Suppression of LPA-Mediated Telomerase Activity 
Chapters 2 and 3 show that VEGF and LPA induce telomerase activity by ERK 1/2-
dependent transcriptional activation within the -976 to the -378 bp hTERT telomerase 
promoter regions.  In addition, the current experiments show that vitamin E consistently 
abrogates LPA-mediated telomerase activity through transcriptional inhibition of the 
hTERT -976 to -578 bp promoter regions.   
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Chapter IV 
EGF-Mediated Telomerase Activity is Pyk2-Dependent 
 in Ovarian Cancer Cells 
Abstract 
Telomerase is present in over 90% of human cancers suggesting that this enzyme 
is required for tumor cell proliferation and malignant progression.  Several growth factors 
including epidermal growth factor (EGF) have been identified as regulators of telomerase 
activity, but the exact molecular mechanisms of this regulation are unknown.  Since EGF 
can stimulate growth of normal ovarian surface epithelial (OSE) as well as ovarian cancer 
cells, and EGF receptors are present on both normal and malignant ovarian cells, these 
experiments sought to investigate the potential role for EGF to regulate telomerase 
activity in ovarian cancer cells.  The results of my experiments show that: (1) while none 
of the ovarian cancer cell lines examined secreted significant amounts of EGF, 
exogenous EGF directly activated telomerase activity; (2) EGF up-regulated hTERT 
transcription; (3) EGF-mediated telomerase activity was ERK 1/2-dependent; (4) EGF 
positively targeted the core, 181 bp, promoter of the hTERT promoter where Sp1 and c-
Myc are major transcription factors involved in EGF-mediated telomerase activity in 
ovarian cancers; and (5) these experiments also identified proline-rich tyrosine kinase 2 
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(Pyk2) as a novel key mediator of EGF-mediated telomerase activity.  Therefore, these 
experiments suggest that EGF stimulation of telomerase activity in ovarian cancer cells is 
mediated by Sp1 and c-Myc transcription factors within the hTERT core promoter in an 
ERK 1/2 /Pyk2-dependent manner.   
Introduction 
Telomerase is a ribonucleoprotein responsible for DNA telomeric maintenance at 
the ends of chromosomes.  Telomerase synthesizes and adds the six-base motif 
(TTAGGG)n in humans to the ends of linear chromosomes maintaining telomere length 
stability that otherwise would gradually erode after each cell replication [89].  
Telomerase activity has been detected in over 90% of solid tumor cells.  It is also 
activated in embryonic and germline cells, but not in normal somatic cells, with the 
exception of some stem cells that are involved, for example, in tissue renewal [89].  Since 
telomerase plays a vital role in tumor cell survival and proliferation, telomerase is a 
potentially important therapeutic target.  
Transcriptional activation of the hTERT gene is a critical, initial rate-limiting step 
in hTERT function and telomerase activity.  Multiple binding sites for transcriptional 
regulation reflect the complex regulation of the hTERT gene.  Growth factors are known 
to regulate telomerase activity through transcriptional activation in several cancers.  One 
of these growth factors is epidermal growth factor (EGF) [176, 178].  EGF is one of the 
EGF receptor ligands known to participate in various cellular functions such as 
proliferation, migration, differentiation, and survival [284]  EGF is a 53 amino acid 
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polypeptide with a molecular weight of 6045 Da [285].  It acts by binding to both low 
affinity (KD = 12 nM) and high affinity (KD = 1050 ρM) sites on cells that express 
epidermal growth factor receptor (EGFR) [286] and stimulating the intrinsic protein-
tyrosine kinase activity of the receptor.  Growth-related responses to EGF include the 
induction of nuclear proto-oncogene expression, such as Fos, Jun, and Myc.   
EGFR belongs to the EGF/ERbB family of type I receptor tyrosine kinases that 
participate in various cellular functions.  They are composed of four members, 
EGFR/ErbB1/HER1, ErbB2/Neu/HER2, ErbB3/HER3, and ErbB4/HER4 [284].  These 
receptors are single chain transmembrane polypeptide proteins possessing three different 
domains: (1) the extracellular domain which allows ligand binding to receptors, (2) the 
transmembrane domain involved in dimerization interaction between receptors, and (3) 
the intracellular tyrosine kinase domain that phosphorylates tyrosine residues on substrate 
proteins.  The cytoplasmic domain also consists of a carboxy-terminal tail containing 
tyrosine autophosphorylation sites linking these receptors to proteins containing Src 
homology 2 and phosphotyrosine-binding domains.  These proteins allow activation of 
several signal transduction molecules such as Pyk2 and ERK 1/2 [284].   
The other members of the EGFR ligand family consist of heparin binding EGF-
like growth factor (HB-EGF), transforming growth factor-α (TGF-α), epiregulin, 
amphiregulin, epigen, β-cellulin (BTC), and four neuregulins (NRG-1, 2, 3, and 4) [284, 
287, 288].  Each ligand binds to the extracellular domain of ErbB receptors inducing the 
formation of homo- and heterodimers of the receptors, which allows the intrinsic tyrosine 
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kinase domain to be activated, resulting in a phosphorylation of specific tyrosine residues 
within the cytoplasmic tail of the receptor [284].  These autophosphorylated residues 
serve as docking sites for a variety of signaling molecules, whose recruitment leads to the 
activation of intracellular signaling pathways [284].    
Several G protein-coupled receptors (GPCRs) have been shown to transactivate 
EGFR through GPCR agonists including thrombin, ANG II, endothelin-1, carbachol, and 
LPA [289].  This transactivation mediates several critical downstream signals functions, 
such as ERK activation, c-fos induction, and cell proliferation [289-291].  In order for 
this transactivation to occur, second messengers directly and/or signal transduction 
pathways operated by second messengers, such as elevation of intracellular Ca2+ [292, 
293], activation of protein kinase C (PKC) [293], and generation of reactive oxygen 
species (ROS) [294-296] are required.  In addition, metalloproteases are also required for 
EGFR transactivation by several GPCR agonists [297, 298].  Lastly, cytosolic 
nonreceptors tyrosine kinase such as Src and Pyk2 are also required in the EGFR 
transactivation [299, 300].   
Pyk2 is a cytoplasmic non-receptor tyrosine kinase related to focal adhesion 
kinase that can be activated by several extracellular signals including inflammatory 
cytokines, UV radiation, tumor necrosis factor-α, and changes in calcium levels [301].  
Overexpression or altered activity of Pyk2 has been linked to changes in cell adhesion, as 
well as invasion and metastasis of various malignancies such as prostate cancer [302].  
Pyk2 can activate phosphatidylinositol triphosphate kinase (PI-3-K) [303], which, in turn, 
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can phosphorylate jun N-terminal kinase (JNK) [304]  as well as the mitogen-activated 
protein kinase (MAPK) signaling pathway [305].  Therefore, Pyk2 appears to be a key 
mediator of intracellular signaling linking a variety of extracellular stimuli to the MAPK, 
PI-3-K, and JNK pathways depending on the context of bound effector systems [306-
308].  For instance, our laboratory found that Pyk2 mediates exogenous stress-mediated 
regulation of telomerase through PI-3-K/JNK signaling pathways in human ovarian 
cancer cells [253].   
Since gene amplification leading to EGFR overexpression and EGFR 
transactivation are found in carcinomas of the breast, lung, and ovaries [309-311], and 
Pyk2 is important in EGFR transactivation and telomerase activity, the purpose of these 
experiments was to determine whether EGF could regulate telomerase activity in ovarian 
cancer cells in a Pyk2-dependent manner.  The data show that exogenous EGF directly 
activated telomerase through an up-regulation of hTERT transcription via the ERK 1/2 
pathway and positively targeted transcription binding sequences within the hTERT core 
promoter where transcription factors Sp1 and c-Myc appear to be major mediators of 
EGF-induced telomerase activity of ovarian cancer cells.  In addition, when ovarian 
cancer cells were transfected with wild type Pyk2, EGF-mediated telomerase activity was 
markedly increased.  In contrast, transfection with kinase deficient Pyk2 abolished EGF-
mediated induction of telomerase activity.  In summary, these experiments suggest that 
EGF stimulation of telomerase activity in ovarian cancer cells is mediated by Sp1 and c-
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Myc transcription factors within the hTERT core promoter in an ERK 1/2 /Pyk2-
dependent manner. 
Materials and Methods 
Cell Lines and Tissue Culture 
Telomerase-positive ovarian carcinoma cell lines SKOV3, ES-2, C-13, PA-1, SW 
626, and one non-tumorigenic SV40 large-T antigen-transfected human ovarian surface 
epithelial (IOSE) cell line, FHIOSE 118, derived from normal ovarian surface epithelium 
were used [217].  Cells were cultured in Medium 199/MDCB 105 (Sigma, St. Louis, 
MO) supplemented with 5% fetal bovine serum (FBS) (Hyclone, Logan, UT) and 10 
µg/mL Gentamicin (GIBCO, NY).  The cells were incubated at 37ºC with 5% CO2 / 95% 
air.   
EGF, HGF, VEGF ELISA 
To measure EGF, HGF, and VEGF production by cultured cells, equal amounts of 
conditioned media from cell lines were collected, centrifuged at 500 g for 5 minutes at 
room temperature to remove any cellular debris and the supernatants were frozen at -
80°C until assayed using the quantitative sandwich enzyme-linked immunosorbent assay 
(ELISA) (R&D Systems, Minneapolis, MN) according to the manufacturers instructions 
for EGF, HGF, and VEGF levels, respectively.  The enzymatic reactions were detected at 
450 nm using the ELx800 Universal Microplate Reader (Bio-Tek Instruments, Inc., 
Winooski, VT) and the results expressed as ρg/mL of triplicate experiments ± S.E. 
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Treatment with EGF, EGF Receptor Inhibitor, and ERK 1/2 Inhibitor 
Cells were grown in 0.1% FBS media for at least 18 hours prior to treatment with 
2 ng/mL of EGF dissolved in 0.1% BSA (Sigma, St. Louis, MO), 50 nM of AG 1478  
EGF receptor-specific inhibitor tyrphostin dissolved in DMSO (BioSource, Camarillo, 
CA) or  10 µg/mL U0126 ERK 1/2 inhibitor dissolved in methanol (Cell Signaling, 
Beverly, MA) in 0.1% FBS media for 0 to 24 hours and then collected to perform the 
necessary analyses.   
Telomerase Assay 
To quantitatively detect changes in telomerase activity levels, cells were assayed 
for telomerase activity using the telomerase polymerase chain reaction-sandwich 
enzyme-linked immunosorbent assay (PCR-ELISA) following manufacturers protocol 
(Roche, Indianapolis, IN) and as previously described [218].  This assay has been 
demonstrated to be as sensitive as the radioactive telomere repeat amplification protocol 
(TRAP) assay [261].  Briefly, cells were washed with DPBS, trypsinized, and centrifuged 
at 500 g for five minutes.  Pellets were washed twice in DPBS, then resuspended in 150 
µL of lysis buffer (10 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 1 mM EGTA, 0.1 mM 
PMSF, 5 mM β-mercaptoethanol, 0.5% CHAPS, 10% glycerol).  The cell pellets were 
kept on ice for 30 minutes and then centrifuged at 100,000 g for 60 minutes at 4°C.  
Supernates were then assayed using the Bio-Rad DC Protein Assay (Bio-Rad, Hercules, 
CA) to determine protein concentration following detergent solubilization according to 
manufacturers instructions.  To perform the telomerase PCR-ELISA within a linear 
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range, all of the cells extracts equivalent to 3 µg of protein were used.  Following PCR-
ELISA, telomerase activity was detected using the ELx800 Universal Microplate Reader 
(Bio-Tek Instruments, Inc., Winooski, VT) and recorded as optical density ± S.E.   
RT-PCR 
To examine the contribution of transcriptional control of telomerase regulation by 
EGF, RT-PCR was performed as previously described [218].  Total RNA was collected 
using TRIzol reagent (Invitrogen, Carlsbad, CA).  One microgram total RNA, oligo(dT), 
and reverse transcriptase were used to generate single-strand cDNA for each sample.  The 
cDNA samples were amplified using the Perkin-Elmer (Palo Alto, CA) GeneAmp kit.  
The hTERT primers used were hTERT-S (CGGAAGAGTGTCTGGAGCCAA) and 
hTERT-AS (GGATGAAGCGGAG TCTGGA) oligonucleotides (Sigma Genosys, The 
Woodlands, TX) and with β-actin primers Actin-S 
(CAGGTCATCACCATTGGCAATGAGC) and Actin-AS (GATGTCCACGT 
CACACTTCATGA) for an internal control.  The amplified products were then separated 
by electrophoresis on a 1% agarose gel, stained with 1X SyberGreen (FMC Bioproducts, 
Rocklan, ME) and analyzed with the Kodak EDAS 120 Digital Analysis System.  Net 
hTERT mRNA intensities from treated samples were normalized to their corresponding 
β-actin mRNA levels. 
Western Blot Analysis 
For Western blot analyses, cell lysates were prepared in CHAPS lysis buffer as 
previously described [219]. Protein concentrations of cell lysates were determined using 
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the Bio-Rad Dc Protein Assay (Bio-Rad, Hercules, CA) in accordance to the 
manufacturers instructions.  Protein extracts (20 µg) were solubilized in SDS gel loading 
buffer (60 mM Tris base, 2% SDS, 10% glycerol, and 5% β-mercaptoethanol) and 
separated via 12.5% or 7.5% SDS-PAGE and electroblotted onto Hybond-ECL 
nitrocellulose membranes (Amersham Life Sciences, Piscataway, NJ) by wet transfer.  
Immunoblotting was performed using antibodies against ERK 1/2 (1:1000), MAPK 
phospho-ERK 1/2 (1:1000), anti-Myc (1:1000; Cell Signaling, Beverly, MA), anti-Sp1 
(1:1000; Santa Cruz Biotechnology, Santa Cruz, CA), anti-phosphorylated and 
unphosphorylated Pyk2 (1:1000; Upstate Biotechnology, Lake Placid, NY).  β-actin 
(1:5000, Sigma Aldrich, St. Louis, MO) was used as loading control.  Blots were 
visualized using the ECL Western Blotting Analysis System (Amersham Pharmacia 
Biotech, Piscataway, NJ) according to the manufacturers instructions.  Blots were 
scanned and analyzed with Life Sciences GE Healthcare ImageQuant image analysis 
software (GE Healthcare Bio-Sciences Corp., Piscataway, NJ).  Values reported for target 
proteins were normalized to the blots' respective β-actin levels.  
Luciferase Reporter Assay 
To measure hTERT promoter activity, the full-length (pGL3-1375), and deleted 
hTERT promoter-luciferase constructs (pGL3-1175, -976, -776, -578, -378, -181) and 
mutated hTERT core promoter constructs (hTERT/-181E1/m, hTERT/-181E1, 2/m, 
hTERT/-181 Sp1/m) were used as previously described [220].  To determine whether 
Pyk2 mediated EGF induction of telomerase, Myc-tagged wild-type (WT) Pyk2 or Myc-
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tagged kinase-deficient (KD) Pyk2 were used as previously described [253].  To examine 
the roles of c-Myc and Sp1 in EGF-mediated telomerase activity, cells were transfected 
with 0.5 µM c-Myc siRNA or ± 1 µM Sp1 siRNA (Santa Cruz Biotechnology, Santa 
Cruz, CA).  SW 626 cells were incubated in 0.1% FBS for 24 h and then transiently co-
transfected with 3 µg of DNA and 1U of β-galactosidase cDNA using Lipofectamine 
reagent (Invitrogen, Carlsbad, CA) in serum- and antibiotic-free media.  Cultures were 
replenished with serum 1 h after transfection.  Expression of luciferase was measured 48 
h after transfection using the Luciferase Assay System (Promega, Madison, WI) 
according to the manufacturers instructions.  At time of collection, cells were 
microscopically observed to ensure cell viability with no signs of apoptosis using parallel 
cultures transfected with green fluorescent protein (GFP). Transcriptional activity was 
expressed as relative luciferase activity ± S.E., after normalization with β-galactosidase 
activity. 
Statistical Analysis 
Samples for ELISA, telomerase PCR-ELISA, RT-PCR, and reporter assays were 
run in triplicate, and the data were subjected to the Students t test for determination of 
statistical significance.  
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Results 
EGF induces telomerase activity  
To determine whether EGF stimulated telomerase activity in ovarian cancer cells, 
time-dependent and dose-dependent assays were performed (Figures 25A and B).  
Telomerase activity was measured by PCR-ELISA for 0 to 24 hours following treatment 
with 0 to 25 ng/mL of EGF, respectively.  Cells were incubated in media containing 0.1% 
FBS for 24 hours prior to culturing them in the presence or absence of EGF.  Figure 25A 
shows that at one hour, EGF elicited greatest increase in telomerase activity in ovarian 
cancer cells PA-1 (40%) and SW 626 (63%).  Treatments with 2 ng/mL EGF resulted in a 
two-fold increase in telomerase activity in ovarian cancer cells PA-1 and SW 626 (Figure 
25B).  A panel of additional ovarian cancer cell lines, SKOV3, C13, PA-1, ES-2, and SW 
626 were treated with 2 ng/mL EGF for an hour to confirm EGF-mediated stimulation of 
telomerase activity (Figure 26).  While none of the ovarian cancer cell lines examined 
produced significant EGF (Figure 26, inset), exogenous EGF increased telomerase 
activity.   Each cell line showed a significant increase in telomerase activity compared to 
their respective controls (SKOV3 38%, C13 28%, PA-1 44%, ES-2 48%, and SW 626 
49%) (Figure 26).  Different dosages of EGF or treatment intervals did not affect 
telomerase activity in telomerase negative FHIOSE 118 cell line serving as control 
(Figures 25 and 26).   
To demonstrate specificity of EGF for telomerase activity in ovarian cancer cells, 
SW 626 cancer cells were treated with the EGF receptor-specific inhibitor tyrphostin AG 
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1478 (Figure 27).  While AG 1478 did not significantly suppress endogenous telomerase 
activity in SW 626, AG 1478 inhibited EGF-stimulated telomerase activity by 300% 
(Figure 27).  In contrast, telomerase-negative FHIOSE 118 cell were unaffected by EGF 
inhibition serving as control.  Treatments with AG 1478 diluent, DMSO, did not alter 
EGF stimulation of telomerase activity.     
EGF-stimulated telomerase activity is transcription-dependent 
 RT-PCR was performed to determine the relative levels of hTERT mRNA in PA-
1 and SW 626 cells following EGF stimulation (Figure 28).  PA-1 and SW 626 cells 
showed an increase of 123% and 127%, respectively, in relative levels of hTERT mRNA 
transcript after 1h EGF treatment when normalized to β-actin (Figure 28).   
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Figure 25 EGF Regulation of Telomerase Activity is Time- and Dose-Dependent 
Telomerase activity was measured by PCR-ELISA in cultured human ovarian FHIOSE 
118, PA-1, and SW 626 cells treated with 2 ng/mL EGF for 0 to 24 hours (A) and 0 to 25 
ng/mL EGF for 1 hour (B) in 0.1% FBS.  * indicates the statistical significance of levels 
of telomerase activity in PA-1 and SW 626 cancer cells treated compared to untreated 
controls.  Data from three independent experiments were quantified and expressed as 
mean absorbance at 490 nm ± S.E. 
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Figure 26 EGF Stimulates Telomerase Activity in Human Ovarian Cancer Cells 
SKOV3, C13, PA-1, ES-2, SW 626, and FHIOSE 118 ovarian cell lines were treated with 
± 2 ng/mL for 1 hour in 0.1% FBS, collected and examined for telomerase activity by 
PCR-ELISA.  For telomerase analysis, data from three independent experiments were 
quantified and expressed as mean absorbance at 490 nm ± S.E.  * indicates statistically 
significant differences in telomerase activity between EGF treated cell lines and their 
untreated counterparts.  (Inset) Enzyme-linked immunosorbent assay analyses of secreted 
EGF, HGF, and VEGF protein concentrations in conditioned media of SKOV3, C13, PA-
1, ES-2, SW 626, and FHIOSE 118 cell lines.   
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Figure 27 EGF is Specific to Stimulate Telomerase Activity 
To show specificity of EGF to stimulate telomerase activity, FHIOSE 118 and SW 626 
cells were treated with ± 2 ng/mL EGF for 1 hour ± 50 nM EGF receptor inhibitor, AG 
1478 in 0.1% FBS.  Samples were also treated with AG 1478 diluent, DMSO, serving as 
control.  p values indicate statistical differences between telomerase activity in SW 626 
cancer cells treated with EGF vs. untreated control (*), AG 1478 treated SW 626 cells vs. 
untreated control (~), EGF + DMSO treated SW 626 cells vs. untreated control (^), and 
EGF + AG 1478 treated SW 626 cells vs. EGF treated SW 626 cells (**).  Data from 
three independent experiments were quantified and expressed as mean absorbance at 490 
nm ± S.E. 
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Figure 28 EGF Stimulation of Telomerase Activity is Transcription-Dependent 
PA-1 and SW 626 cells were incubated ± 2 ng/mL EGF for 0, 30, 45 minutes, 1 and 2 
hours in triplicate and examined by RT-PCR for hTERT mRNA.  Results are expressed 
as mRNA expression normalized to corresponding β-actin mRNA levels.  * indicates the 
statistical significance of hTERT mRNA levels in PA-1 and SW 626 cells treated with 2 
ng/mL EGF compared to untreated controls.  Graphical representations provided below 
of respective blots showing net intensities of hTERT in PA-1 and SW 626 cancer cells 
relative to β-actin mRNAs. 
 
EGF-induced telomerase activity is Pyk2-dependent  
 To determine whether Pyk2 was a mediator in EGF-induced telomerase activity 
in human ovarian cancer cells, SW 626 cancer cells were transfected with c-Myc tagged 
wild type Pyk2 (Pyk2 WT) or c-Myc tagged kinase deficient Pyk2 (Pyk2 KD) and treated 
cells with 2 ng/mL EGF and ± 50 ng/mL EGFR inhibitor, AG 1478, an hour prior to 
collection.  After 48 hours, protein lysates were obtained and tested for transfection 
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efficiency via Western blot analysis for Pyk2 protein levels (Figure 29, inset).  To study 
the effect of Pyk2 on telomerase activity, PCR-ELISA was performed.  Pyk2 KD reduced 
EGF-mediated induction of telomerase activity by 47% compared to EGF treated SW 626 
cells (Figure 29).   In contrast, SW 626 cells transfected with Pyk2 WT demonstrated 
increased telomerase activity by 54%.  Furthermore, SW 626 cells transfected with Pyk2 
WT and treated with 2 ng/mL EGF showed an increase in telomerase activity by 64% 
compared to EGF treated SW 626 cells (Figure 29). 
EGF-stimulated telomerase activity is ERK 1/2 dependent 
In agreement with Maida et al [176], EGF increased ERK 1/2 phosphorylation in 
ovarian cancer cells (Figure 30).  Western blot and densitometric analyses showed that 
EGF increased ERK 1/2 phosphorylation by 34% and 52% in PA-1 and SW 626 ovarian 
cancer cells, respectively (Figure 30, inset).  Cells treated with U0126 showed a 
significant decrease in EGF-mediated ERK 1/2 phosphorylation by 71% and 39% in PA-
1 and SW 626 ovarian cancer cells, respectively (Figure 30, inset).  In agreement with 
results obtained in Figure 26, EGF stimulated telomerase activity by 47% in PA-1 and 
SW 626 cells.  Inhibition of ERK 1/2 by U0126 abrogated EGF-stimulated telomerase 
activity by 84% and 76% in PA-1 and SW 626 cells, respectively (Figure 30), confirming 
a role for ERK 1/2 in EGF-stimulated telomerase activity in ovarian cancer cells.   
To determine whether Pyk2 induction of telomerase was also ERK 1/2-dependent, 
Western blot analyses were performed (Figure 31, inset).  ERK1/2 phosphorylation 
increased in EGF-treated SW 626 cells when compared to untreated controls.  ERK 1/2 
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phosphorylation was also increased in all Pyk2 WT transfected SW 626 cells.  In 
contrast, ERK 1/2 phosphorylation decreased in all Pyk2 KD transfected SW 626 cells 
(Figure 31, inset).   
 
Figure 29 EGF Stimulation of Telomerase Activity is Pyk2-Dependent 
SW 626 cells were transfected with Myc-tagged Pyk2-KD or Pyk2-WT and treated with 
± 2 ng/mL EGF and ± 50 nM EGFR inhibitor AG 1478 and assayed for telomerase 
activity by PCR-ELISA.  Results were expressed as mean optical density at 490 nm for 
triplicate samples ± S.E.  p values indicate the statistical significance of EGF treated cells 
vs. untreated control (*), Pyk2 KD transfected cells vs. untreated control (~), Pyk2 KD + 
EGF vs. EGF treated cells (~~), Pyk2 KD + EGF + AG 1478 vs. EGF treated cells (~~~), 
Pyk2 WT vs. untreated control (^), Pyk2 WT + EGF vs. EGF treated cells (^^), Pyk2 WT 
+ EGF + AG 1478 vs. EGF treated cells (^^^).  (A, inset) Cell lysates were analyzed for 
Pyk2 expression and ERK 1/2 phosphorylation by Western blot.  β-actin was used as 
loading control.  For telomerase analysis, results were expressed as mean optical density 
at 490 nm for triplicate samples ± S.E.   
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Figure 30 EGF Stimulation of Telomerase Activity is Via the ERK 1/2 Signaling 
Pathway 
Cultures of PA-1 and SW 626 cells were treated with ± 10µM U0126 and ± 2 ng/mL 
EGF for 1 hour in 0.1% FBS.  Cells were then harvested and analyzed for telomerase 
activity.  Results were expressed as mean optical density at 490 nm for triplicate samples 
± S.E.  p values indicate the statistical significance between EGF treated cells vs. 
untreated controls (*), U0126 treated cells vs. untreated controls (~), and EGF + U0126 
treated cells vs. EGF treated cells (`).  (A, inset) Western blot analysis was performed to 
confirm U0126 inhibition of ERK 1/2 phosphorylation.  β-actin was used as the loading 
control.   
  
hTERT core promoter region is required for EGF stimulation of hTERT promoter 
activity 
 Reporter assays were performed using full length, deletion promoter constructs, 
and deletion core promoter constructs to identify the hTERT promoter region responsive 
to EGF (Figure 31).  The full length hTERT promoter (PGL3-1375) was induced by EGF 
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by 61% compared to endogenous promoter activity (Figure 31).  However, EGF 
stimulated maximal activity at the core hTERT promoter regions (PGL3-181) by 67% 
compared to endogenous core promoter activity (Figure 31).  The hTERT core promoter 
contains two c-Myc binding sites and five Sp1 binding sites known to be activators of 
hTERT transcription [312].  To further evaluate the binding sites responsive to EGF-
mediated induction of telomerase within the core promoter, hTERT luciferase reporters 
containing mutations of E-box 1 (hTERT/-181E1/m), E-box 2 (hTERT/-181E1, 2/m), and 
all Sp1 sites (hTERT/-181Sp1/m) were performed [220].  Luciferase assays showed that 
EGF-induced hTERT promoter activity was abrogated by mutation of Sp1 sites.  In 
contrast, mutation of E-box 1 did not affect EGF-induced hTERT promoter activity.  
Interestingly, mutation of E-box 1 and 2 showed a decrease, but not complete abrogation, 
in core promoter transactivation when compared to the full core promoter activity.  My 
results suggest that Sp1 binding sites within the hTERT core promoter are essential and 
that E-box 2 might be important in EGF-induced telomerase activity in human ovarian 
cancer cells.   
To confirm specificity of EGF induction of the hTERT core promoter, reporter 
assays were also performed on SW 626 cells treated with 2 ng/mL EGF and either 50 nM 
EGF receptor inhibitor AG 1478, 10 µg/mL ERK 1/2 inhibitor U0126 (Figure 31).  EGF 
failed to induce activity of the 1375-bp and 181-bp regions of the hTERT promoter when 
co-treated with AG 1478 (Figure 31).  Co-treatments with EGFR inhibitor, AG 1478, also 
confirmed the importance of Sp1 and E-box 2 in EGF-mediated transactivation of the 
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hTERT core promoter.  In addition, U0126 significantly suppressed EGF-mediated 
induction of luciferase activity of the 1375-bp and 181-bp regions of the hTERT 
promoter (Figure 31). 
To confirm EGF-stimulated of telomerase activity was Pyk2-dependent in ovarian 
cancer cells, reporter assays were also performed on SW 626 cells transfected with 
hTERT core promoter or hTERT core promoter mutations, Pyk2 WT or Pyk2 DN and 
treated with ± 2 ng/mL EGF (Figure 32).  Overexpression of wild type Pyk2 significantly 
enhanced EGF-mediated hTERT core promoter transactivation, while the kinase deficient 
Pyk2 significantly blocked EGF-mediated transactivation of the core promoter (Figure 
32).  These findings suggest that Pyk2 is an important mediator of EGF-mediated 
stimulated telomerase in ovarian cancer cells.  
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Figure 32 Pyk2 Drives hTERT Core Promoter Activity 
SW 626 cells were transfected with hTERT core promoter and deletion hTERT core 
promoter luciferase constructs along with pCMV-β-galactosidase expression vector and 
co-transfected with ± c-Myc-tagged Pyk2-KD and ± Pyk2-WT.  An hour prior to 
collection, cells were treated with ± 2 ng/mL EGF.  GFP was used to monitor transfection 
efficiency.  Results were expressed as the mean luciferase activity ± S.E. from triplicate 
samples.  p values indicate statistical differences between luciferase assays in EGF 
treated cells vs. untreated control (*), Pyk2 DN + EGF treated cells vs. Pyk2 DN treated 
cells (~), and Pyk2 WT + EGF treated cells vs. Pyk2 WT treated (^).   
 
EGF-Mediated Telomerase Activity is c-Myc- and Sp1-Dependent  
Since binding sites for transcription factors, c-Myc and Sp1, are present within the 
hTERT core promoter, Western blot (Figure 33, inset), PCR-ELISA (Figure 33), and 
reporter analyses (Figure 34) were performed using c-Myc and Sp1 siRNAs to confirm 
whether these transcription factors are important in EGF-mediated telomerase activity.  
SW 626 cells were transfected with ± 0.5 µM c-Myc siRNA ± 1 µM Sp1 siRNA and 
treated with ± 2 ng/mL EGF.  c-Myc and Sp1 siRNAs reduced endogenous c-Myc and 
Sp1 protein levels in SW 626 cells when transfected with their respective siRNAs and 
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abolished EGF-mediated increased c-Myc and Sp1 levels compared to c-Myc and Sp1 
siRNAs untransfected controls as determined by Western blot analyses (Figure 33, inset).  
In addition, c-Myc and Sp1 siRNAs were sufficient to decrease endogenous telomerase 
activity by 50% and 65%, and decreased EGF-mediated telomerase activity by 47% and 
46%, respectively (Figure 33).  Furthermore, reporter assays using hTERT full length, 
core promoter, and core promoter mutated constructs were performed to confirm that c-
Myc and Sp1 are important transcription factors in EGF-mediated telomerase activity.  
Compared to endogenous promoter activity, the full length hTERT promoter was 
inhibited by c-Myc and Sp1 siRNAs by 67% and 80%, respectively, and EGF-induced 
full length hTERT promoter activity was inhibited by 63% and 50%, respectively (Figure 
34A).  When both siRNAs were transfected into the cells, EGF-mediated telomerase 
activity was reduced by 75% (Figure 34A).  In regards to the hTERT core promoter, 
endogenous hTERT core promoter activity was inhibited by Sp1 and c-Myc siRNAs by 
67% and 33%, respectively (Figure 34A).  EGF-induced hTERT core promoter activity 
was suppressed by 67% and 44% in the cells transfected with Sp1 and c-Myc siRNAs, 
respectively (Figure 34A).  When both Sp1 and c-Myc siRNAs were combined, EGF-
mediated hTERT core promoter activity was inhibited by 78% (Figure 34A).  To confirm 
that EGF-mediated telomerase activity in ovarian cancer cells require Sp1 and c-Myc 
transcription factors, reporter assays using mutant core promoter reporter plasmids and 
Sp1 and c-Myc siRNAs were performed (Figure 34B).  The results revealed that 
abrogation of Sp1 sites significantly reduced responsiveness to EGF (Figure 34B).  Even 
though, abrogation of the E-boxes by substitution mutations still allowed for some EGF-
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induced hTERT activation, indicates that c-Myc along with Sp1 may play a role in EGF-
mediated telomerase activity in ovarian cancer cells (Figure 34B).   
 
Figure 33 EGF-Mediated Telomerase Activity is c-Myc- and Sp1-Dependent 
SW 626 cells were transfected with ± 0.5 µM c-Myc siRNA ± 1 µM Sp1 siRNA and 
treated with ± 2 ng/mL EGF for an hour prior to collection.  Cells were then harvested 
and analyzed for c-Myc and Sp1 expression by Western blot (Inset) and telomerase 
activity by PCR-ELISA. For Western blot analyses, β-actin was used as loading control.  
p values indicate the statistical significance of EGF treated cells vs. untreated controls 
(*), c-Myc, Sp1 transfected cells vs. untreated controls (~, ~~), c-Myc, Sp1 transfected + 
EGF treated cells vs. EGF treated cells (^, ^^), and c-Myc and Sp1 transfected + EGF 
treated cells vs. EGF treated cells (**).  For telomerase analyses, results were expressed 
as mean optical density at 490 nm for triplicate samples ± S.E.  
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Discussion 
The EGFR is overexpressed in over 70% of primary ovarian cancers [313] and 
has been directly associated with poor postoperative prognosis due to, in part, 
chemotherapy resistance [314-316].  Furthermore, the activation of the EGFR signaling 
pathway in cancer cells is associated with increased cell proliferation, angiogenesis, 
metastasis, and decreased apoptosis [317].  Since EGF receptors are constitutively 
activated in ovarian cancer and EGF, an EGFR ligand, promotes OSE cell growth, the 
potential contribution of EGF in the regulation of telomerase activity was examined.  A 
better understanding of this signaling pathway, then, could provide insight on developing 
effective chemotherapeutic drugs.  These experiments showed EGF stimulates telomerase 
activity in a transcription-dependent manner by activating the Sp1 and c-Myc binding 
sites within the hTERT core promoter via the Pyk2/ERK 1/2 signaling pathway (Figure 
35).   
The core promoter region contains an E box binding factor and putative protein 
binding sites for transcription factors Sp1 and AP2 [138].  E box binding proteins are 
known to heterodimerize with a variety of transcription factors with helix-loop-helix 
domains including Myc-related family members and Max-related family members [228].  
c-Myc may form dimers with Max which then bind to specific E-box binding sites to 
transactivate the hTERT promoter.  However, c-Myc can also dimerize with Mad1 at the 
same binding site to suppress hTERT transcription [229].  Interestingly, Budiyanto et al 
showed a correlation between c-Myc and Sp1 transcription factors and EGFR when 
squamous cell carcinoma cell line treated with EGFR inhibitor, AG 1478, significantly 
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reduced the expression of c-Myc and Sp1.  In addition, they showed that AG 1478 
increased the level of Mad-1 protein expression [178].  These results and my luciferase 
reporter assays results are consistent with the notion that Sp1 and c-Myc cooperate to 
activate hTERT transcription and telomerase activity [138, 146, 318]. 
However, previous studies have also shown that EGF can regulate telomerase in 
vulvar cancer and squamous cell carcinoma through Ets-mediated transactivation of 
TERT via the MAPK signaling pathway [176, 178].  In contrast, my results show that 
Sp1 and c-Myc transcription factors appear to be the major transcription factors involved 
in EGF-mediated stimulation of telomerase in ovarian cancer cells.  Yet, neither c-Myc 
and Sp1 siRNAs transfections nor E-box and Sp1 mutated binding sites in the hTERT 
core promoter did not completely abolish all promoter activity in my studies.  Therefore, 
since Ets binding sites in the hTERT core promoter were intact in all of my experiments, 
Ets may account for non-c-Myc and/or Sp1-mediated hTERT activity.   
Of particular interest, these experiments provide novel findings that Pyk2 kinase 
activity was essential for EGF-mediated telomerase activity in ovarian cancer cells 
(Figure 35).  So, Pyk2-mediated telomerase activity may represent a novel molecular 
mechanism by which Pyk2 regulates tumor cell proliferation and/or apoptosis to confer 
increased tumor cell survival.  Pyk2 along with other nonreceptor tyrosine kinases such 
as focal adhesion kinase (FAK), are important signaling effectors linking integrin and 
growth factor receptor signaling to cell proliferation, migration, survival, and apoptosis in 
many cell types [304, 319].  FAK is the prototypical signaling effector coupling integrin-
matrix interactions to intracellular signaling events [320].  It is rapidly activated 
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following integrin engagement and exerts downstream effects by serving both as an 
effector kinase as well as a scaffold protein for various molecules including Src and PI-3-
K [321].  A variety of extracellular signals that elevate intracellular calcium 
concentrations and stress signals mediated by tumor necrosis factor (TNF-α) or 
ultraviolet (UV) irradiation lead to activation of Pyk2 [304, 319, 321].  Pyk2 has been 
implicated in the regulation of migration and invasion of glioma, endothelial, smooth 
muscle cells, and intestinal cells [322-325].  In tumors, Pyk2 expression decreases with 
increasing tumor grade in prostatic adenocarcinoma [301].  Likewise, Meyer et al showed 
that hyperactivation of receptor tyrosine kinase, FGFR3, in multiple myeloma cells 
recruited Pyk2 leading to activation of proliferative and/or anti-apoptotic signaling 
pathways [326].   
Consequently, the clinical relevance of my research in current developmental 
efforts of monoclonal antibodies and receptor tyrosine kinase inhibitors (TKIs) where 
binding of EGF growth or active active site of the kinase are blocked is two fold.  Since 
EGF increases telomerase activity and Pyk2 plays an important role in signal transduction 
of EGF/EGFR interactions, further studies pursuing either monoclonal antibody to EGF 
or TKIs for EGFR may lead to more effective and/or improved drugs development for 
ovarian cancer.   
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Figure 35 Schematic Representation of the Proposed Signaling Pathway for 
EGF-Induced of Telomerase Activity in Ovarian Cancer Cells 
The data of this chapter show that EGF stimulation of telomerase activity was mediated 
by Sp1 and c-Myc transcription factors within the hTERT core promoter in an ERK 1/2 
/Pyk2-dependent manner. 
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Chapter V 
Conclusions 
Re-expression of telomerase in cancers maintains genomic stability of critically 
shortened telomeres allowing for continuous cell proliferation and immortalization [327].  
As a clinical consequence, however, the re-expression of telomerase in cancers suggests 
that telomerase may be an important target for chemotherapeutic intervention [328, 329].  
By specifically targeting telomerase, it may be possible to restore normal telomeric 
attrition resulting in cellular senescence and apoptosis.  Therefore, it is important to 
identify positive and negative regulators of telomerase activity in order to develop novel 
therapies against telomerase.   
Novel findings herein indicated that VEGF is not limited to regulation of 
endothelial cell growth and survival, but also appears to regulate telomerase activity in 
ovarian cancer cells via an ERK 1/2 transcription-dependent activation of the Sp1 binding 
sites within the 976- to 378-bp hTERT promoter region.  These findings provide a 
plausible mechanism for the presence of VEGF receptors in non-endothelial cells.  
Consequently, the effectiveness of anti-angiogenic therapies may function to suppress 
new blood vessel growth from local endothelial cells to ovarian tumors as well as to 
inhibit telomerase activity within the tumor cells.   
This study also identified telomerase as a novel molecular target of LPA.  As a 
positive upstream regulator of VEGF, LPA-mediated telomerase activity in ovarian 
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cancer was also found to occur in an ERK 1/2-dependent manner to activate the Sp1 
binding sites within the 976- to 378-bp hTERT promoter regions.  Therefore, while most 
clinical trials focus on LPA as a potential biomarker for ovarian cancer, this study 
provides novel information on the function of LPA that may contribute to the malignant 
phenotype of ovarian cancer. 
Furthermore, this study reported that the anti-tumorigenic role of vitamin E role in 
ovarian cancer is two fold.  Vitamin E suppressed endogenous telomerase activity and 
abrogated LPA-induced telomerase activity in ovarian cancer cells.  Though in vivo 
testing and clinical studies need to be performed to further evaluate the clinical 
usefulness of vitamin E for chemotherapeutic efficacy, the present study shows that, by 
targeting telomerase, supplemental vitamin E may be a valuable adjuvant for prevention 
of ovarian cancer and/or improved sensitivity to standard chemotherapeutic agents.   
Lastly, this study demonstrated that EGF-induced telomerase activity in ovarian 
cancer cells is ERK 1/2- and Pyk2-dependent.  EGF-mediated telomerase activity 
activated c-Myc and Sp1 binding sites within the hTERT core promoter region.  Since 
overexpression of EGFR correlates with increased metastasis, decreased survival, and 
poor prognosis, further studies on the inhibition of EGFR-associated tyrosine kinases 
currently in clinical trials for the treatment of solid tumors, including ovarian cancer are 
warranted as they may block major signaling pathways for telomerase activation as a 
mechanism of antitumor activity of these drugs. 
Interestingly, VEGF, LPA, and EGF all transduced activation of telomerase in 
ovarian cancer cells through the activation of ERK 1/2.  These findings are consistent 
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with the notion of MAPK as a cellular central hub controlling the effects of growth 
factors and stresses on cellular proliferation and differentiation [330, 331].   
In this study, VEGF-, LPA-, and EGF-elicited transcriptional effects on the 
hTERT gene were mediated by Sp1 and c-Myc transcription factors with VEGF and LPA 
targeting Sp1 binding sites within the 976- to 378-bp hTERT promoter regions and EGF 
targeting Sp1 and c-Myc binding sites within the hTERT core promoter.  Consequently, 
c-Myc and Sp1 appear to be major transcription factors associated with hTERT 
transcription and it is not surprising, then, that they are overexpressed with malignant 
transformation [229, 318].  The ability of multiple growth factors to positively regulate 
telomerase using redundant pathways in ovarian cancer indicates both the importance of 
telomerase activation to maintain the malignant phenotype as well as the complexity of 
telomerase regulation.  
In summary, chemosensitivity is a crucial prognostic factor for ovarian cancer and 
levels of or changes in telomerase may predict therapeutic outcome.  Understanding the 
mechanisms that positively and negatively regulate telomerase, especially those that 
involve VEGF/LPA, EGF, and vitamin E, could enhance cellular sensitivity to 
chemotherapeutic agents resulting in an improved therapeutic efficacy and clinical 
outcome.    
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